{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:09:40Z","timestamp":1793725780527,"version":"4.6.1"},"reference-count":272,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-03006-7","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T03:19:35Z","timestamp":1756437575000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["RETRACTED ARTICLE: miRNA-mediated resistance mechanisms in prostate cancer: implications for targeted therapy and metastatic progression"],"prefix":"10.1007","volume":"42","author":[{"given":"Mostafa M.","family":"Mostafa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa K. Abd","family":"El-Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4824-3485","authenticated-orcid":false,"given":"Doha El-Sayed","family":"Ellakwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"issue":"1","key":"3006_CR1","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7\u201333.","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"3006_CR2","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41585-022-00638-6","volume":"19","author":"H Van Poppel","year":"2022","unstructured":"Van Poppel H, Albreht T, Basu P, Hogenhout R, Collen S, Roobol M. Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future. Nat Rev Urol. 2022;19(9):562\u201372.","journal-title":"Nat Rev Urol"},{"key":"3006_CR3","doi-asserted-by":"crossref","unstructured":"Mumuni S, O\u2019Donnell C, Doody O, editors. The risk factors and screening uptake for prostate cancer: a scoping review. In: Healthcare; 2023: MDPI.","DOI":"10.3390\/healthcare11202780"},{"issue":"6 Suppl 1","key":"3006_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.urology.2003.10.013","volume":"62","author":"ED Crawford","year":"2003","unstructured":"Crawford ED. Epidemiology of prostate cancer. Urology. 2003;62(6 Suppl 1):3\u201312.","journal-title":"Urology"},{"issue":"1","key":"3006_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00243-0","volume":"7","author":"RJ Rebello","year":"2021","unstructured":"Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, et al. Prostate cancer. Nat Rev Dis Primers. 2021;7(1): 9.","journal-title":"Nat Rev Dis Primers"},{"key":"3006_CR6","doi-asserted-by":"crossref","unstructured":"Graham NJ, Souter LH, Salami SS, editors. A systematic review of family history, race\/ethnicity, and genetic risk on prostate cancer detection and outcomes: considerations in PSA-based screening. In: Urologic oncology: seminars and original investigations; 2024: Elsevier.","DOI":"10.1016\/j.urolonc.2024.06.002"},{"issue":"12","key":"3006_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/jfbc.14447","volume":"46","author":"EM Shaaban","year":"2022","unstructured":"Shaaban EM, Ellakwa DE, Elaraby NM, Amr KS, Mohamadin AM. The effect of insulin-loaded gold and carboxymethyl chitosan nanoparticles on gene expression of glucokinase and pyruvate kinase in rats with diabetes type 1. J Food Biochem. 2022;46(12): e14447.","journal-title":"J Food Biochem"},{"key":"3006_CR8","doi-asserted-by":"crossref","unstructured":"Sundaresan VM, Smani S, Rajwa P, Renzulli J, Sprenkle PC, Kim IY, et al., editors. Prostate-specific antigen screening for prostate cancer: diagnostic performance, clinical thresholds, and strategies for refinement. In: Urologic oncology: seminars and original investigations; 2024: Elsevier.","DOI":"10.1016\/j.urolonc.2024.06.003"},{"key":"3006_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.mgene.2018.07.010","volume":"18","author":"S Ali","year":"2018","unstructured":"Ali S, Ellakwa D, Emara S, El-Sabbagh N. The role of chemerin and vaspin in Egyptian patients with viral hepatitis C. Meta Gene. 2018;18:23\u201330.","journal-title":"Meta Gene"},{"issue":"6","key":"3006_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0130308","volume":"10","author":"R Chen","year":"2015","unstructured":"Chen R, Huang Y, Cai X, Xie L, He D, Zhou L, et al. Age-specific cutoff value for the application of percent free prostate-specific antigen (PSA) in Chinese men with serum PSA levels of 4.0\u201310.0 ng\/ml. PLoS ONE. 2015;10(6): e0130308.","journal-title":"PLoS ONE"},{"key":"3006_CR11","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s13193-012-0142-6","volume":"3","author":"M Adhyam","year":"2012","unstructured":"Adhyam M, Gupta AK. A review on the clinical utility of PSA in cancer prostate. Indian J Surg Oncol. 2012;3:120\u20139.","journal-title":"Indian J Surg Oncol"},{"issue":"3","key":"3006_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/jbt.23284","volume":"37","author":"HM Ali","year":"2023","unstructured":"Ali HM, Ellakwa DES, Elaraby NM, Zaher AM, Amr KS. Study the association of microRNA polymorphisms (miR-146a, miR-4513) with the risk of coronary heart diseases in Egyptian population. J Biochem Mol Toxicol. 2023;37(3): e23284. https:\/\/doi.org\/10.1002\/jbt.23284.","journal-title":"J Biochem Mol Toxicol"},{"issue":"6","key":"3006_CR13","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1038\/sj.bjc.6605822","volume":"103","author":"SM Edwards","year":"2010","unstructured":"Edwards SM, Evans DG, Hope Q, Norman AR, Barbachano Y, Bullock S, et al. Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. Br J Cancer. 2010;103(6):918\u201324.","journal-title":"Br J Cancer"},{"issue":"1","key":"3006_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3121\/cmr.1.1.21","volume":"1","author":"KQ Zhang","year":"2003","unstructured":"Zhang KQ, Salzman SA, Reding DJ, Suarez BK, Catalona WJ, Burmester JK. Genetics of prostate cancer. Clin Med Res. 2003;1(1):21\u20138.","journal-title":"Clin Med Res"},{"issue":"5","key":"3006_CR15","first-page":"1142","volume":"56","author":"KA Cooney","year":"1996","unstructured":"Cooney KA, Wetzel JC, Merajver SD, Macoska JA, Singleton TP, Wojno KJ. Distinct regions of allelic loss on 13q in prostate cancer. Cancer Res. 1996;56(5):1142\u20135.","journal-title":"Cancer Res"},{"issue":"4","key":"3006_CR16","doi-asserted-by":"publisher","first-page":"445","DOI":"10.5603\/rpor.101528","volume":"29","author":"M Lopez-Valcarcel","year":"2024","unstructured":"Lopez-Valcarcel M, Valcarcel F, Velasco J, Zapata I, Rodriguez R, Cardona J, et al. Stereotactic ablative radiotherapy (SABR) for pelvic nodal oligorecurrence in prostate cancer. Rep Pract Oncol Radiother. 2024;29(4):445\u201353.","journal-title":"Rep Pract Oncol Radiother"},{"key":"3006_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.canlet.2017.08.011","volume":"407","author":"R Kanwal","year":"2017","unstructured":"Kanwal R, Plaga AR, Liu X, Shukla GC, Gupta S. Micrornas in prostate cancer: functional role as biomarkers. Cancer Lett. 2017;407:9\u201320.","journal-title":"Cancer Lett"},{"issue":"1","key":"3006_CR18","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1159\/000519861","volume":"100","author":"V Achard","year":"2021","unstructured":"Achard V, Putora PM, Omlin A, Zilli T, Fischer S. Metastatic prostate cancer: treatment options. Oncology. 2021;100(1):48\u201359.","journal-title":"Oncology"},{"issue":"5","key":"3006_CR19","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.urology.2015.07.034","volume":"86","author":"F Saad","year":"2015","unstructured":"Saad F, Fizazi K. Androgen deprivation therapy and secondary hormone therapy in the management of hormone-sensitive and castration-resistant prostate cancer. Urology. 2015;86(5):852\u201361.","journal-title":"Urology"},{"issue":"3","key":"3006_CR20","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.clgc.2020.08.008","volume":"19","author":"ND Shore","year":"2021","unstructured":"Shore ND, Morgans AK, Ryan CJ. Resetting the bar of castration resistance - understanding androgen dynamics in therapy resistance and treatment choice in prostate cancer. Clin Genitourin Cancer. 2021;19(3):199\u2013207.","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"3006_CR21","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nrg3162","volume":"13","author":"AE Pasquinelli","year":"2012","unstructured":"Pasquinelli AE. MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. Nat Rev Genet. 2012;13(4):271\u201382.","journal-title":"Nat Rev Genet"},{"issue":"13","key":"3006_CR22","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1016\/j.febslet.2010.08.009","volume":"585","author":"SA Melo","year":"2011","unstructured":"Melo SA, Esteller M. Dysregulation of micrornas in cancer: playing with fire. FEBS Lett. 2011;585(13):2087\u201399.","journal-title":"FEBS Lett"},{"issue":"2","key":"3006_CR23","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s13277-014-2664-8","volume":"36","author":"A Zekri","year":"2015","unstructured":"Zekri A, Ghaffari SH, Ghanizadeh-Vesali S, Yaghmaie M, Salmaninejad A, Alimoghaddam K, et al. AZD1152-HQPA induces growth arrest and apoptosis in androgen-dependent prostate cancer cell line (LNCaP) via producing aneugenic micronuclei and polyploidy. Tumor Biol. 2015;36(2):623\u201332.","journal-title":"Tumor Biol"},{"key":"3006_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-7601-0_1","volume":"1733","author":"SY Ying","year":"2018","unstructured":"Ying SY, Chang DC, Lin SL. The MicroRNA. Methods Mol Biol. 2018;1733:1\u201325.","journal-title":"Methods Mol Biol"},{"issue":"9","key":"3006_CR25","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrg2843","volume":"11","author":"J Krol","year":"2010","unstructured":"Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 2010;11(9):597\u2013610.","journal-title":"Nat Rev Genet"},{"issue":"5880","key":"3006_CR26","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1126\/science.1159151","volume":"320","author":"P Brodersen","year":"2008","unstructured":"Brodersen P, Sakvarelidze-Achard L, Bruun-Rasmussen M, Dunoyer P, Yamamoto YY, Sieburth L, et al. Widespread translational inhibition by plant miRNAs and siRNAs. Science. 2008;320(5880):1185\u201390.","journal-title":"Science"},{"issue":"10a","key":"3006_CR27","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1101\/gr.2722704","volume":"14","author":"A Rodriguez","year":"2004","unstructured":"Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A. Identification of mammalian microRNA host genes and transcription units. Genome Res. 2004;14(10a):1902\u201310.","journal-title":"Genome Res"},{"issue":"6","key":"3006_CR28","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2174\/1389557515666150324123208","volume":"15","author":"B Simonson","year":"2015","unstructured":"Simonson B, Das S. Microrna therapeutics: the next magic bullet? Mini Rev Med Chem. 2015;15(6):467\u201374.","journal-title":"Mini Rev Med Chem"},{"issue":"4","key":"3006_CR29","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.jmii.2023.04.005","volume":"56","author":"RM Hassan","year":"2023","unstructured":"Hassan RM, Elanany MG, Mostafa MM, Yousef RHA, Salem ST. Whole genome characterization of methicillin resistant Staphylococcus aureus in an Egyptian tertiary care hospital. J Microbiol Immunol Infect. 2023;56(4):802\u201314.","journal-title":"J Microbiol Immunol Infect"},{"issue":"23","key":"3006_CR30","doi-asserted-by":"publisher","first-page":"9667","DOI":"10.1073\/pnas.0703820104","volume":"104","author":"JR Lytle","year":"2007","unstructured":"Lytle JR, Yario TA, Steitz JA. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5\u2019 UTR as in the 3\u2019 UTR. Proc Natl Acad Sci USA. 2007;104(23):9667\u201372.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"3006_CR31","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1261\/rna.2384610","volume":"16","author":"F Moretti","year":"2010","unstructured":"Moretti F, Thermann R, Hentze MW. Mechanism of translational regulation by miR-2 from sites in the 5\u2019 untranslated region or the open reading frame. RNA. 2010;16(12):2493\u2013502.","journal-title":"RNA"},{"issue":"1","key":"3006_CR32","doi-asserted-by":"publisher","first-page":"2458434","DOI":"10.1080\/20565623.2025.2458434","volume":"11","author":"DES Ellakwa","year":"2025","unstructured":"Ellakwa DES, Rashed LA, Ali OS, El-Sabbagh NA. A study to determine the effect of nano-selenium and thymoquinone on the Nrf2 gene expression in Alzheimer\u2019s disease. Future Sci OA. 2025;11(1):2458434.","journal-title":"Future Sci OA"},{"key":"3006_CR33","volume":"18","author":"DES Ellakwa","year":"2021","unstructured":"Ellakwa DES, Abdel-Hamid M, Ashour MSED, Khairy LES, Ali OSM. Identifying of HBV DNA in liver tissues of chronic hepatitis and hepatocellular carcinoma to study the Hepatitis B virus silent infection in Egyptian patients. Ecol Genet Genom. 2021;18: 100077.","journal-title":"Ecol Genet Genom"},{"issue":"1","key":"3006_CR34","first-page":"1","volume":"398","author":"DE Ellakwa","year":"2025","unstructured":"Ellakwa DE, Abdelmalek MA, Mostafa MM, Ellakwa TE, Wadan AS. Micrornas predict and modulate responses to chemotherapy in leukemic patients. Naunyn-Schmiedebergs Arch Pharmacol. 2025;398(1):1\u201318.","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"issue":"7","key":"3006_CR35","doi-asserted-by":"publisher","first-page":"9927","DOI":"10.1002\/jcp.27948","volume":"234","author":"SG Aghdam","year":"2019","unstructured":"Aghdam SG, Ebrazeh M, Hemmatzadeh M, Seyfizadeh N, Shabgah AG, Azizi G, et al. The role of microRNAs in prostate cancer migration, invasion, and metastasis. J Cell Physiol. 2019;234(7):9927\u201342.","journal-title":"J Cell Physiol"},{"issue":"5","key":"3006_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20051154","volume":"20","author":"L Moya","year":"2019","unstructured":"Moya L, Meijer J, Schubert S, Matin F, Batra J. Assessment of miR-98-5p, miR-152-3p, miR-326 and miR-4289 expression as biomarker for prostate cancer diagnosis. Int J Mol Sci. 2019;20(5): 1154.","journal-title":"Int J Mol Sci"},{"key":"3006_CR37","unstructured":"Atiaa, A. G., Abd E-Kader, S. M., & Ellakwa, D. E. S. Integrative physiotherapy in burn rehabilitation: innovations in physical, psychological, and technological interventions\u2014a narrative review. J Bodywork Movement Ther."},{"issue":"5","key":"3006_CR38","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1007\/s11845-024-03752-z","volume":"193","author":"DES Ellakwa","year":"2024","unstructured":"Ellakwa DES, Amr KS, Zaki ME, Refeat M, Banksle HM. Zinc finger 259 gene polymorphisms in Egyptian patients with metabolic syndrome and its association with dyslipidemia (1971-). Irish J Med Sci. 2024;193(5):2313\u201323.","journal-title":"Irish J Med Sci"},{"issue":"4","key":"3006_CR39","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3390\/diagnostics10040188","volume":"10","author":"J Freds\u00f8e","year":"2020","unstructured":"Freds\u00f8e J, Rasmussen AK, Mouritzen P, Bjerre MT, \u00d8stergren P, Fode M, et al. Profiling of circulating microRNAs in prostate cancer reveals diagnostic biomarker potential. Diagnostics. 2020;10(4):188.","journal-title":"Diagnostics"},{"issue":"4","key":"3006_CR40","doi-asserted-by":"publisher","first-page":"L17","DOI":"10.1530\/ERC-14-0234","volume":"21","author":"LA Selth","year":"2014","unstructured":"Selth LA, Roberts MJ, Chow C, Marshall VR, Vincent AD, Butler LM, et al. Human seminal fluid as a source of prostate cancer-specific microRNA biomarkers. Endocr Relat Cancer. 2014;21(4):L17\u201321.","journal-title":"Endocr Relat Cancer"},{"issue":"7","key":"3006_CR41","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.3390\/jcm4071369","volume":"4","author":"BD Kelly","year":"2015","unstructured":"Kelly BD, Miller N, Sweeney KJ, Durkan GC, Rogers E, Walsh K, et al. A circulating microRNA signature as a biomarker for prostate cancer in a high risk group. J Clin Med. 2015;4(7):1369\u201379.","journal-title":"J Clin Med"},{"key":"3006_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.genrep.2024.102056","volume":"37","author":"DES Ellakwa","year":"2024","unstructured":"Ellakwa DES, El Nakeeb SMS, Abd El Mohsen SA. The impact of hydrogen sulfide on mesenchymal stem cells in rats suffering from liver fibrosis via suppression of TGF-\u03b2 signaling. Gene Reports. 2024;37: 102056.","journal-title":"Gene Reports"},{"issue":"28","key":"3006_CR43","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1038\/s41388-024-03076-3","volume":"43","author":"GAD Metcalf","year":"2024","unstructured":"Metcalf GAD. MicroRNAs: circulating biomarkers for the early detection of imperceptible cancers via biosensor and machine-learning advances. Oncogene. 2024;43(28):2135\u201342.","journal-title":"Oncogene"},{"key":"3006_CR44","doi-asserted-by":"crossref","unstructured":"Chen S, Lu C, Lin S, Sun C, Wen Z, Ge Z, et al. A panel based on three-miRNAs as diagnostic biomarker for prostate cancer. Frontiers in Genetics. 2024;Volume 15 - 2024.","DOI":"10.3389\/fgene.2024.1371441"},{"issue":"4","key":"3006_CR45","volume":"16","author":"S Kumari","year":"2024","unstructured":"Kumari S, Manoj A, Rungta S, Kumar M, Prasad G, Kumar D, et al. Discovery and Validation of Novel microRNA Panel for Non-Invasive Prediction of Prostate Cancer. Cureus. 2024;16(4): e58207.","journal-title":"Cureus"},{"issue":"11","key":"3006_CR46","first-page":"14335","volume":"8","author":"S Xu","year":"2015","unstructured":"Xu S, Yi X-M, Zhou W-Q, Cheng W, Ge J-P, Zhang Z-Y. Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer. Int J Clin Exp Pathol. 2015;8(11):14335.","journal-title":"Int J Clin Exp Pathol"},{"key":"3006_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.humgen.2024.201281","author":"DES Ellakwa","year":"2024","unstructured":"Ellakwa DES, Elsheikh-Hassan AF, Ellakwa TE, Abdelmalek MA. Recent update on future therapeutic strategies for COVID-19 vaccination with omicron variant. Human Gene. 2024. https:\/\/doi.org\/10.1016\/j.humgen.2024.201281.","journal-title":"Human Gene"},{"issue":"2","key":"3006_CR48","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3892\/ijo.2017.4038","volume":"51","author":"W Chen","year":"2017","unstructured":"Chen W, Liu Y, Chen H, Ning H, Ding K. Loss of miR-449a-caused PrLZ overexpression promotes prostate cancer metastasis. Int J Oncol. 2017;51(2):435\u201344.","journal-title":"Int J Oncol"},{"key":"3006_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2490-12-14","volume":"12","author":"ST Reis","year":"2012","unstructured":"Reis ST, Pontes-Junior J, Antunes AA, Dall\u2019Oglio MF, Dip N, Passerotti CC, et al. miR-21 may acts as an oncomir by targeting RECK, a matrix metalloproteinase regulator, in prostate cancer. BMC Urol. 2012;12:1\u20137.","journal-title":"BMC Urol"},{"key":"3006_CR50","doi-asserted-by":"publisher","DOI":"10.1007\/s11845-024-03732-3","author":"DES Ellakwa","year":"2024","unstructured":"Ellakwa DES, Rashed LA, El-Mandoury AAA, Younis NF. Epigenetic alterations in preeclampsia: a focus on microRNA149 and tetrahydrofolate reductase gene polymorphisms in Egyptian women. Irish J Med Sci. 2024. https:\/\/doi.org\/10.1007\/s11845-024-03732-3.","journal-title":"Irish J Med Sci"},{"issue":"2","key":"3006_CR51","first-page":"721","volume":"64","author":"TE Ellakwa","year":"2021","unstructured":"Ellakwa TE, Ellakwa DE. Enhancement of the solubility and the dissolution rate of oral nimodipine formulation with solid dispersion. Egypt J Chem. 2021;64(2):721\u20138.","journal-title":"Egypt J Chem"},{"issue":"3","key":"3006_CR52","doi-asserted-by":"publisher","first-page":"292","DOI":"10.7150\/jca.11038","volume":"6","author":"KR Leite","year":"2015","unstructured":"Leite KR, Reis ST, Viana N, Morais DR, Moura CM, Silva IA, et al. Controlling RECK miR21 promotes tumor cell invasion and is related to biochemical recurrence in prostate cancer. J Cancer. 2015;6(3):292.","journal-title":"J Cancer"},{"key":"3006_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-015-0209-7","volume":"34","author":"J Guo","year":"2015","unstructured":"Guo J, Wang M, Liu X. MicroRNA-195 suppresses tumor cell proliferation and metastasis by directly targeting BCOX1 in prostate carcinoma. J Exp Clin Cancer Res. 2015;34:1\u20138.","journal-title":"J Exp Clin Cancer Res"},{"issue":"7","key":"3006_CR54","first-page":"8394","volume":"8","author":"X Sun","year":"2015","unstructured":"Sun X, Yang Z, Zhang Y, He J, Wang F, Su P, et al. Prognostic implications of tissue and serum levels of microRNA-128 in human prostate cancer. Int J Clin Exp Pathol. 2015;8(7):8394.","journal-title":"Int J Clin Exp Pathol"},{"issue":"1","key":"3006_CR55","doi-asserted-by":"publisher","first-page":"202","DOI":"10.21608\/aijpms.2024.185070.1186","volume":"5","author":"NF Younis","year":"2025","unstructured":"Younis NF, Rashed LA, El-mandoury AA, Ellakwa DE. Genetic factors in preeclamptic egyptian women: relation with arginine vasopressin; a case\u2013control study. Azhar Int J Pharm Med Sci. 2025;5(1):202\u201315. https:\/\/doi.org\/10.21608\/aijpms.2024.185070.1186.","journal-title":"Azhar Int J Pharm Med Sci"},{"key":"3006_CR56","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1007\/s00210-024-03509-6","volume":"398","author":"A Raza","year":"2024","unstructured":"Raza A, Fatima P, Yasmeen B, Rana ZA, Ellakwa DES. From resistance to remedy: the role of clustered regularly interspaced short palindromic repeats system in combating antimicrobial resistance\u2014a review. Naunyn-Schmiedeberg\u2019s Arch Pharmacol. 2024;398:2259\u201373.","journal-title":"Naunyn-Schmiedeberg's Arch Pharmacol"},{"issue":"3","key":"3006_CR57","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3390\/ijms17030421","volume":"17","author":"G Bertoli","year":"2016","unstructured":"Bertoli G, Cava C, Castiglioni I. MicroRNAs as biomarkers for diagnosis, Prognosis and theranostics in prostate cancer. Int J Mol Sci. 2016;17(3):421.","journal-title":"Int J Mol Sci"},{"key":"3006_CR58","doi-asserted-by":"crossref","unstructured":"Ellakwa, D.E.S., Mansour, A.S., Gorgui, R., Banksle, H.M. Cerebrolysin in post-TBI recovery: pharmacology and clinical evidence.\u00a0Gene Reports 2025;102202.","DOI":"10.1016\/j.genrep.2025.102202"},{"issue":"5","key":"3006_CR59","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1002\/ijc.24827","volume":"126","author":"A Schaefer","year":"2010","unstructured":"Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer. 2010;126(5):1166\u201376.","journal-title":"Int J Cancer"},{"issue":"1","key":"3006_CR60","doi-asserted-by":"publisher","first-page":"12345","DOI":"10.1038\/s41598-020-69290-7","volume":"10","author":"R Parra-Medina","year":"2020","unstructured":"Parra-Medina R, L\u00f3pez-Kleine L, Ram\u00edrez-Clavijo S, Pay\u00e1n-G\u00f3mez C. Identification of candidate miRNAs in early-onset and late-onset prostate cancer by network analysis. Sci Rep. 2020;10(1):12345.","journal-title":"Sci Rep"},{"issue":"3","key":"3006_CR61","doi-asserted-by":"publisher","first-page":"443","DOI":"10.21608\/ejchem.2017.3685","volume":"60","author":"TE Ellakwa","year":"2017","unstructured":"Ellakwa TE, Fahmy A, Ellakwa DE. Influence of poloxmer on the dissolution properties of mosapride and its pharmaceutical tablet formulation. Egypt J Chem. 2017;60(3):443\u201351.","journal-title":"Egypt J Chem"},{"key":"3006_CR62","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-024-03076-w","author":"DES Ellakwa","year":"2024","unstructured":"Ellakwa DES, Mushtaq N, Khan S, Jabbar A, Abdelmalek MA, Wadan AHS, et al. Molecular functions of microRNAs in colorectal cancer: recent roles in proliferation, angiogenesis, apoptosis, and chemoresistance. Naunyn-Schmiedeberg\u2019s Arch Pharmacol. 2024. https:\/\/doi.org\/10.1007\/s00210-024-03076-w.","journal-title":"Naunyn-Schmiedeberg's Arch Pharmacol"},{"issue":"1","key":"3006_CR63","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41598-018-36854-7","volume":"9","author":"E Richardsen","year":"2019","unstructured":"Richardsen E, Andersen S, Melb\u00f8-J\u00f8rgensen C, Rakaee M, Ness N, Al-Saad S, et al. MicroRNA 141 is associated to outcome and aggressive tumor characteristics in prostate cancer. Sci Rep. 2019;9(1):386.","journal-title":"Sci Rep"},{"issue":"4","key":"3006_CR64","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.afju.2018.11.006","volume":"24","author":"R Ali","year":"2018","unstructured":"Ali R, El Tabbakh S, El Delgawy W, Kotb A, Desouky MN. microRNA-141 as a diagnostic and prognostic biomarker for prostate cancer in Egyptian population: pilot study. Afr J Urol. 2018;24(4):347\u201352.","journal-title":"Afr J Urol"},{"key":"3006_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-020-01186-6","volume":"19","author":"M Labb\u00e9","year":"2020","unstructured":"Labb\u00e9 M, Hoey C, Ray J, Potiron V, Supiot S, Liu SK, et al. microRNAs identified in prostate cancer: correlative studies on response to ionizing radiation. Mol Cancer. 2020;19:1\u201318.","journal-title":"Mol Cancer"},{"key":"3006_CR66","doi-asserted-by":"crossref","unstructured":"Raza A, Mushtaq N, Jabbar A, Ellakwa DES. Antimicrobial peptides: a promising solution to combat colistin and carbapenem resistance.\u00a0Gene Reports 2024; 101935.","DOI":"10.1016\/j.genrep.2024.101935"},{"issue":"2","key":"3006_CR67","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/sj.bjc.6605742","volume":"103","author":"MS Zaman","year":"2010","unstructured":"Zaman MS, Chen Y, Deng G, Shahryari V, Suh SO, Saini S, et al. The functional significance of microRNA-145 in prostate cancer. Br J Cancer. 2010;103(2):256\u201364.","journal-title":"Br J Cancer"},{"issue":"13","key":"3006_CR68","doi-asserted-by":"publisher","first-page":"5412","DOI":"10.1158\/1538-7445.AM2018-5412","volume":"78","author":"I Benedetti","year":"2018","unstructured":"Benedetti I, Rebollo J, Reyes N. miR155 and miR9 expression in human prostate cancer cell lines and prostate cancer tissue. Cancer Res. 2018;78(13):5412.","journal-title":"Cancer Res"},{"issue":"6","key":"3006_CR69","doi-asserted-by":"publisher","first-page":"e65064","DOI":"10.1371\/journal.pone.0065064","volume":"8","author":"M Schubert","year":"2013","unstructured":"Schubert M, Spahn M, Kneitz S, Scholz CJ, Joniau S, Stroebel P, et al. Distinct microRNA expression profile in prostate cancer patients with early clinical failure and the impact of let-7 as prognostic marker in high-risk prostate cancer. PLoS ONE. 2013;8(6):e65064.","journal-title":"PLoS ONE."},{"issue":"1","key":"3006_CR70","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3892\/ol.2017.6163","volume":"14","author":"J Zhang","year":"2017","unstructured":"Zhang J, Wang X, Wang Y, Peng R, Lin Z, Wang Y, et al. Low expression of microRNA-30C promotes prostate cancer cells invasion involved in downregulation of KRAS protein. Oncol Lett. 2017;14(1):363\u20138.","journal-title":"Oncol Lett"},{"issue":"4","key":"3006_CR71","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s13577-017-0170-1","volume":"30","author":"Q Zhu","year":"2017","unstructured":"Zhu Q, Li H, Li Y, Jiang L. MicroRNA-30a functions as tumor suppressor and inhibits the proliferation and invasion of prostate cancer cells by down-regulation of SIX1. Hum Cell. 2017;30(4):290\u20139.","journal-title":"Hum Cell"},{"issue":"4","key":"3006_CR72","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1158\/0008-5472.CAN-10-1031","volume":"71","author":"D Sun","year":"2011","unstructured":"Sun D, Lee YS, Malhotra A, Kim HK, Matecic M, Evans C, et al. miR-99 family of microRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation. Can Res. 2011;71(4):1313\u201324.","journal-title":"Can Res"},{"key":"3006_CR73","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-024-03592-9","author":"AS Neamah","year":"2024","unstructured":"Neamah AS, Wadan AHS, Lafta FM, Elakwa DES. The potential role of targeting the leptin receptor as a treatment for breast cancer in the context of hyperleptinemia: a literature review. Naunyn-Schmiedeberg\u2019s Arch Pharmacol. 2024. https:\/\/doi.org\/10.1007\/s00210-024-03592-9.","journal-title":"Naunyn-Schmiedeberg's Arch Pharmacol"},{"issue":"8","key":"3006_CR74","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1080\/15384047.2019.1599659","volume":"20","author":"C Guan","year":"2019","unstructured":"Guan C, Zhang L, Wang S, Long L, Zhou H, Qian S, et al. Upregulation of MicroRNA-21 promotes tumorigenesis of prostate cancer cells by targeting KLF5. Cancer Biol Ther. 2019;20(8):1149\u201361.","journal-title":"Cancer Biol Ther"},{"key":"3006_CR75","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.omto.2020.03.024","volume":"17","author":"Q Wa","year":"2020","unstructured":"Wa Q, Zou C, Lin Z, Huang S, Peng X, Yang C, et al. Ectopic expression of miR-532-3p suppresses bone metastasis of prostate cancer cells via inactivating NF-\u03baB signaling. Mol Therapy Oncolyt. 2020;17:267\u201377.","journal-title":"Mol Therapy Oncolyt"},{"issue":"6","key":"3006_CR76","first-page":"6187","volume":"18","author":"Z Hu","year":"2019","unstructured":"Hu Z, Guo J, Zhao M, Jiang T, Yang X. Predictive values of miR-129 and miR-139 for efficacy on patients with prostate cancer after chemotherapy and prognostic correlation. Oncol Lett. 2019;18(6):6187\u201395.","journal-title":"Oncol Lett"},{"issue":"6","key":"3006_CR77","doi-asserted-by":"publisher","first-page":"5025","DOI":"10.3892\/mmr.2016.5859","volume":"14","author":"S Xu","year":"2016","unstructured":"Xu S, Yi XM, Zhang ZY, Ge JP, Zhou WQ. MiR-129 predicts prognosis and inhibits cell growth in human prostate carcinoma. Mol Med Rep. 2016;14(6):5025\u201332.","journal-title":"Mol Med Rep"},{"issue":"7","key":"3006_CR78","first-page":"8394","volume":"8","author":"X Sun","year":"2015","unstructured":"Sun X, Yang Z, Zhang Y, He J, Wang F, Su P, et al. Prognostic implications of tissue and serum levels of microRNA-128 in human prostate cancer. Int J Clin Exp Pathol. 2015;8(7):8394\u2013401.","journal-title":"Int J Clin Exp Pathol"},{"key":"3006_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.genrep.2019.100463","volume":"16","author":"H Salem","year":"2019","unstructured":"Salem H, Ellakwa DES, Fouad H, Hamid MA. APOA1 AND APOA2 proteins as prognostic markers for early detection of urinary bladder cancer. Gene Reports. 2019;16: 100463. https:\/\/doi.org\/10.1016\/j.genrep.2019.100463.","journal-title":"Gene Reports"},{"issue":"7068","key":"3006_CR80","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/nature04303","volume":"438","author":"J Kr\u00fctzfeldt","year":"2005","unstructured":"Kr\u00fctzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, et al. Silencing of microRNAs in vivo with \u2018antagomirs.\u2019 Nature. 2005;438(7068):685\u20139.","journal-title":"Nature"},{"issue":"10","key":"3006_CR81","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/nrd3179","volume":"9","author":"R Garzon","year":"2010","unstructured":"Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discovery. 2010;9(10):775\u201389.","journal-title":"Nat Rev Drug Discovery"},{"key":"3006_CR82","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-025-03896-4","author":"Y Khan","year":"2025","unstructured":"Khan Y, Rizvi S, Raza A, Khan A, Hussain S, Khan NU, et al. Tailored therapies for triple-negative breast cancer: current landscape and future perceptions. Naunyn-Schmiedeberg\u2019s Arch Pharmacol. 2025. https:\/\/doi.org\/10.1007\/s00210-025-03896-4.","journal-title":"Naunyn-Schmiedeberg's Arch Pharmacol"},{"issue":"3","key":"3006_CR83","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.bbrc.2020.05.215","volume":"529","author":"K Kim","year":"2020","unstructured":"Kim K, Kim HH, Lee CH, Kim S, Cheon GJ, Kang KW, et al. Therapeutic efficacy of modified anti-miR21 in metastatic prostate cancer. Biochem Biophys Res Commun. 2020;529(3):707\u201313.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"3006_CR84","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/wrna.1213","volume":"5","author":"RO Bak","year":"2014","unstructured":"Bak RO, Mikkelsen JG. miRNA sponges: soaking up miRNAs for regulation of gene expression. Wiley Interdiscipl Rev RNA. 2014;5(3):317\u201333.","journal-title":"Wiley Interdiscipl Rev RNA"},{"issue":"9","key":"3006_CR85","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/nmeth1079","volume":"4","author":"MS Ebert","year":"2007","unstructured":"Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods. 2007;4(9):721\u20136.","journal-title":"Nat Methods"},{"issue":"24","key":"3006_CR86","doi-asserted-by":"publisher","first-page":"20370","DOI":"10.18632\/oncotarget.4827","volume":"6","author":"J Jung","year":"2015","unstructured":"Jung J, Yeom C, Choi YS, Kim S, Lee E, Park MJ, et al. Simultaneous inhibition of multiple oncogenic miRNAs by a multi-potent microRNA sponge. Oncotarget. 2015;6(24):20370\u201387.","journal-title":"Oncotarget"},{"issue":"1","key":"3006_CR87","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1515\/med-2019-0097","volume":"14","author":"Z Xiang","year":"2019","unstructured":"Xiang Z, Xu C, Wu G, Liu B, Wu D. CircRNA-UCK2 increased TET1 inhibits proliferation and invasion of prostate cancer cells via sponge miRNA-767-5p. Open Med. 2019;14(1):833\u201342.","journal-title":"Open Med"},{"issue":"3","key":"3006_CR88","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.celrep.2012.08.030","volume":"2","author":"CH Hsu","year":"2012","unstructured":"Hsu CH, Peng KL, Kang ML, Chen YR, Yang YC, Tsai CH, et al. TET1 suppresses cancer invasion by activating the tissue inhibitors of metalloproteinases. Cell Rep. 2012;2(3):568\u201379.","journal-title":"Cell Rep"},{"key":"3006_CR89","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/978-1-60761-863-8_3","volume":"676","author":"Z Wang","year":"2011","unstructured":"Wang Z. The principles of MiRNA-masking antisense oligonucleotides technology. Methods Mol Biol. 2011;676:43\u20139.","journal-title":"Methods Mol Biol."},{"issue":"1","key":"3006_CR90","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.aspen.2016.11.014","volume":"20","author":"DT Nguyen","year":"2017","unstructured":"Nguyen DT, G\u00f3mez-Zurita J. Diversity and trophic ecology of the Monoleptites group (Chrysomelidae: Galerucinae, Luperini) in the N\u00fai Ch\u00faa National Park (S Vietnam) with description of new species of Monolepta Chevrolat and Paleosepharia Laboissi\u00e8re. J Asia-Pac Entomol. 2017;20(1):65\u201387.","journal-title":"J Asia-Pac Entomol"},{"issue":"8","key":"3006_CR91","doi-asserted-by":"publisher","first-page":"5574","DOI":"10.1002\/jcp.26514","volume":"233","author":"N Hosseinahli","year":"2018","unstructured":"Hosseinahli N, Aghapour M, Duijf PHG, Baradaran B. Treating cancer with microRNA replacement therapy: a literature review. J Cell Physiol. 2018;233(8):5574\u201388.","journal-title":"J Cell Physiol"},{"issue":"8","key":"3006_CR92","doi-asserted-by":"publisher","first-page":"12369","DOI":"10.1002\/jcp.28058","volume":"234","author":"H Mollaei","year":"2019","unstructured":"Mollaei H, Safaralizadeh R, Rostami Z. MicroRNA replacement therapy in cancer. J Cell Physiol. 2019;234(8):12369\u201384.","journal-title":"J Cell Physiol"},{"issue":"1\u20132","key":"3006_CR93","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s11010-013-1576-z","volume":"377","author":"F Qu","year":"2013","unstructured":"Qu F, Cui X, Hong Y, Wang J, Li Y, Chen L, et al. MicroRNA-185 suppresses proliferation, invasion, migration, and tumorigenicity of human prostate cancer cells through targeting androgen receptor. Mol Cell Biochem. 2013;377(1\u20132):121\u201330.","journal-title":"Mol Cell Biochem"},{"issue":"6","key":"3006_CR94","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1667\/RR14185.1","volume":"184","author":"P Gong","year":"2015","unstructured":"Gong P, Zhang T, He D, Hsieh JT. MicroRNA-145 Modulates Tumor Sensitivity to Radiation in Prostate Cancer. Radiat Res. 2015;184(6):630\u20138.","journal-title":"Radiat Res"},{"key":"3006_CR95","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1146\/annurev-pharmtox-010716-104846","volume":"57","author":"CF Bennett","year":"2017","unstructured":"Bennett CF, Baker BF, Pham N, Swayze E, Geary RS. Pharmacology of antisense drugs. Annu Rev Pharmacol Toxicol. 2017;57:81\u2013105.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"3006_CR96","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/j.semcancer.2015.02.006","volume":"35","author":"MA Feitelson","year":"2015","unstructured":"Feitelson MA, Arzumanyan A, Kulathinal RJ, Blain SW, Holcombe RF, Mahajna J, et al. Sustained proliferation in cancer: mechanisms and novel therapeutic targets. Semin Cancer Biol. 2015;35:S25\u201354.","journal-title":"Semin Cancer Biol."},{"issue":"17","key":"3006_CR97","first-page":"3759","volume":"55","author":"E Farber","year":"1995","unstructured":"Farber E. Cell proliferation as a major risk factor for cancer: a concept of doubtful validity. Cancer Res. 1995;55(17):3759\u201362.","journal-title":"Cancer Res"},{"key":"3006_CR98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mgene.2018.07.008","volume":"18","author":"M Abdel-Hamid","year":"2018","unstructured":"Abdel-Hamid M, Nada OH, Ellakwa DES, Ahmed LK. Role of myeloperoxidase in hepatitis C virus related hepatocellular carcinoma. Meta Gene. 2018;18:1\u20138.","journal-title":"Meta Gene"},{"issue":"1","key":"3006_CR99","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.gpb.2015.09.006","volume":"14","author":"Y Fang","year":"2016","unstructured":"Fang Y, Fullwood MJ. Roles, functions, and mechanisms of long non-coding RNAs in cancer. Genom Proteom Bioinform. 2016;14(1):42\u201354.","journal-title":"Genom Proteom Bioinform"},{"issue":"1","key":"3006_CR100","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.apjtm.2016.09.011","volume":"10","author":"Y Yang","year":"2017","unstructured":"Yang Y, Guo JX, Shao ZQ. miR-21 targets and inhibits tumor suppressor gene PTEN to promote prostate cancer cell proliferation and invasion: an experimental study. Asian Pac J Trop Med. 2017;10(1):87\u201391.","journal-title":"Asian Pac J Trop Med"},{"issue":"5","key":"3006_CR101","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/nrm3330","volume":"13","author":"MS Song","year":"2012","unstructured":"Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 2012;13(5):283\u201396.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"8","key":"3006_CR102","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1158\/0008-5472.CAN-08-4112","volume":"69","author":"T Sun","year":"2009","unstructured":"Sun T, Wang Q, Balk S, Brown M, Lee GS, Kantoff P. The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res. 2009;69(8):3356\u201363.","journal-title":"Cancer Res"},{"issue":"4","key":"3006_CR103","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/j.bbrc.2016.12.045","volume":"482","author":"JZ Li","year":"2017","unstructured":"Li JZ, Li J, Wang HQ, Li X, Wen B, Wang YJ. MiR-141-3p promotes prostate cancer cell proliferation through inhibiting kruppel-like factor-9 expression. Biochem Biophys Res Commun. 2017;482(4):1381\u20136.","journal-title":"Biochem Biophys Res Commun"},{"issue":"37","key":"3006_CR104","doi-asserted-by":"publisher","first-page":"59589","DOI":"10.18632\/oncotarget.10729","volume":"7","author":"JM Pickl","year":"2016","unstructured":"Pickl JM, Tichy D, Kuryshev VY, Tolstov Y, Falkenstein M, Sch\u00fcler J, et al. Ago-RIP-Seq identifies Polycomb repressive complex I member CBX7 as a major target of miR-375 in prostate cancer progression. Oncotarget. 2016;7(37):59589\u2013603.","journal-title":"Oncotarget"},{"issue":"5","key":"3006_CR105","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/pros.23478","volume":"78","author":"Z Su","year":"2018","unstructured":"Su Z, Zhang M, Xu M, Li X, Tan J, Xu Y, et al. MicroRNA181c inhibits prostate cancer cell growth and invasion by targeting multiple ERK signaling pathway components. Prostate. 2018;78(5):343\u201352.","journal-title":"Prostate"},{"issue":"5","key":"3006_CR106","first-page":"5121","volume":"14","author":"Y Liu","year":"2017","unstructured":"Liu Y, Xu X, Xu X, Li S, Liang Z, Hu Z, et al. MicroRNA-193a-3p inhibits cell proliferation in prostate cancer by targeting cyclin D1. Oncol Lett. 2017;14(5):5121\u20138.","journal-title":"Oncol Lett"},{"issue":"4","key":"3006_CR107","first-page":"4323","volume":"15","author":"P Hao","year":"2018","unstructured":"Hao P, Kang B, Yao G, Hao W, Ma F. MicroRNA-211 suppresses prostate cancer proliferation by targeting SPARC. Oncol Lett. 2018;15(4):4323\u20139.","journal-title":"Oncol Lett"},{"issue":"11","key":"3006_CR108","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1002\/pros.22664","volume":"73","author":"M Shin","year":"2013","unstructured":"Shin M, Mizokami A, Kim J, Ofude M, Konaka H, Kadono Y, et al. Exogenous SPARC suppresses proliferation and migration of prostate cancer by interacting with integrin \u03b21. Prostate. 2013;73(11):1159\u201370.","journal-title":"Prostate"},{"issue":"6","key":"3006_CR109","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0098833","volume":"9","author":"X Yang","year":"2014","unstructured":"Yang X, Yang Y, Gan R, Zhao L, Li W, Zhou H, et al. Down-regulation of mir-221 and mir-222 restrain prostate cancer cell proliferation and migration that is partly mediated by activation of SIRT1. PLoS ONE. 2014;9(6): e98833.","journal-title":"PLoS ONE"},{"issue":"3\u20134","key":"3006_CR110","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1177\/1947601912475079","volume":"4","author":"Z Lin","year":"2013","unstructured":"Lin Z, Fang D. The roles of SIRT1 in cancer. Genes Cancer. 2013;4(3\u20134):97\u2013104.","journal-title":"Genes Cancer"},{"issue":"21","key":"3006_CR111","doi-asserted-by":"publisher","first-page":"8122","DOI":"10.1128\/MCB.00289-06","volume":"26","author":"M Fu","year":"2006","unstructured":"Fu M, Liu M, Sauve AA, Jiao X, Zhang X, Wu X, et al. Hormonal control of androgen receptor function through SIRT1. Mol Cell Biol. 2006;26(21):8122\u201335.","journal-title":"Mol Cell Biol"},{"issue":"1","key":"3006_CR112","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1158\/1940-6207.CAPR-10-0167","volume":"4","author":"Y Chen","year":"2011","unstructured":"Chen Y, Zaman MS, Deng G, Majid S, Saini S, Liu J, et al. MicroRNAs 221\/222 and genistein-mediated regulation of ARHI tumor suppressor gene in prostate cancer. Cancer Prev Res. 2011;4(1):76\u201386.","journal-title":"Cancer Prev Res"},{"issue":"4","key":"3006_CR113","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrc1840","volume":"6","author":"A Esquela-Kerscher","year":"2006","unstructured":"Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006;6(4):259\u201369.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"3006_CR114","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/nrc1997","volume":"6","author":"GA Calin","year":"2006","unstructured":"Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857\u201366.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"3006_CR115","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/onc.2015.176","volume":"35","author":"D Bonci","year":"2016","unstructured":"Bonci D, Coppola V, Patrizii M, Addario A, Cannistraci A, Francescangeli F, et al. A microRNA code for prostate cancer metastasis. Oncogene. 2016;35(9):1180\u201392.","journal-title":"Oncogene"},{"issue":"2","key":"3006_CR116","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.3390\/ijms13021347","volume":"13","author":"C Lopez-Camarillo","year":"2012","unstructured":"Lopez-Camarillo C, Marchat LA, Arechaga-Ocampo E, Perez-Plasencia C, Moral-Hernandez OD, Castaneda-Ortiz EJ, et al. MetastamiRs: non-coding MicroRNAs driving cancer invasion and metastasis. Int J Mol Sci. 2012;13(2):1347\u201379.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"3006_CR117","doi-asserted-by":"publisher","first-page":"9927","DOI":"10.1002\/jcp.27948","volume":"234","author":"SG Aghdam","year":"2019","unstructured":"Aghdam SG, Ebrazeh M, Hemmatzadeh M, Seyfizadeh N, Shabgah AG, Azizi G, et al. The role of microRNAs in prostate cancer migration, invasion, and metastasis. J Cell Physiol. 2019;234(7):9927\u201342.","journal-title":"J Cell Physiol"},{"issue":"30","key":"3006_CR118","doi-asserted-by":"publisher","first-page":"50240","DOI":"10.18632\/oncotarget.16933","volume":"8","author":"D Vanacore","year":"2017","unstructured":"Vanacore D, Boccellino M, Rossetti S, Cavaliere C, D\u2019Aniello C, Di Franco R, et al. Micrornas in prostate cancer: an overview. Oncotarget. 2017;8(30):50240\u201351.","journal-title":"Oncotarget"},{"issue":"7043","key":"3006_CR119","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/435745a","volume":"435","author":"PS Meltzer","year":"2005","unstructured":"Meltzer PS. Cancer genomics: small RNAs with big impacts. Nature. 2005;435(7043):745\u20136.","journal-title":"Nature"},{"issue":"1","key":"3006_CR120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/mps4010001","volume":"4","author":"G Riolo","year":"2020","unstructured":"Riolo G, Cantara S, Marzocchi C, Ricci C. miRNA targets: from prediction tools to experimental validation. Methods Protoc. 2020;4(1):1.","journal-title":"Methods Protoc."},{"issue":"21","key":"3006_CR121","doi-asserted-by":"publisher","first-page":"6063","DOI":"10.7150\/thno.36735","volume":"9","author":"Y Dai","year":"2019","unstructured":"Dai Y, Wu Z, Lang C, Zhang X, He S, Yang Q, et al. Copy number gain of ZEB1 mediates a double-negative feedback loop with miR-33a-5p that regulates EMT and bone metastasis of prostate cancer dependent on TGF-\u03b2 signaling. Theranostics. 2019;9(21):6063\u201379.","journal-title":"Theranostics"},{"issue":"4","key":"3006_CR122","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1007\/s11684-014-0353-z","volume":"8","author":"R Shi","year":"2014","unstructured":"Shi R, Xiao H, Yang T, Chang L, Tian Y, Wu B, et al. Effects of miR-200C on the migration and invasion abilities of human prostate cancer Du145 cells and the corresponding mechanism. Front Med. 2014;8(4):456\u201363.","journal-title":"Front Med"},{"issue":"3","key":"3006_CR123","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/onc.2012.58","volume":"32","author":"YN Liu","year":"2013","unstructured":"Liu YN, Yin JJ, Abou-Kheir W, Hynes PG, Casey OM, Fang L, et al. MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms. Oncogene. 2013;32(3):296\u2013306.","journal-title":"Oncogene"},{"issue":"4","key":"3006_CR124","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1002\/cam4.2029","volume":"8","author":"H Guan","year":"2019","unstructured":"Guan H, You Z, Wang C, Fang F, Peng R, Mao L, et al. MicroRNA-200a suppresses prostate cancer progression through BRD4\/AR signaling pathway. Cancer Med. 2019;8(4):1474\u201385.","journal-title":"Cancer Med"},{"issue":"3","key":"3006_CR125","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s12253-013-9613-5","volume":"19","author":"SW Xiong","year":"2013","unstructured":"Xiong SW, Lin TX, Xu KW, Dong W, Ling XH, Jiang FN, et al. MicroRNA-335 acts as a candidate tumor suppressor in prostate cancer. Pathol Oncol Res. 2013;19(3):529\u201337.","journal-title":"Pathol Oncol Res"},{"issue":"1","key":"3006_CR126","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1186\/s12885-018-4258-0","volume":"18","author":"DZ Jones","year":"2018","unstructured":"Jones DZ, Schmidt ML, Suman S, Hobbing KR, Barve SS, Gobejishvili L, et al. Micro-RNA-186-5p inhibition attenuates proliferation, anchorage independent growth and invasion in metastatic prostate cancer cells. BMC Cancer. 2018;18(1):421.","journal-title":"BMC Cancer"},{"issue":"1","key":"3006_CR127","first-page":"81","volume":"39","author":"Q Wa","year":"2018","unstructured":"Wa Q, Li L, Lin H, Peng X, Ren D, Huang Y, et al. Downregulation of miR-19a-3p promotes invasion, migration and bone metastasis via activating TGF-\u03b2 signaling in prostate cancer. Oncol Rep. 2018;39(1):81\u201390.","journal-title":"Oncol Rep"},{"issue":"6","key":"3006_CR128","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3892\/ol.2020.12215","volume":"20","author":"L-Y Yao","year":"2020","unstructured":"Yao L-Y, Ma J, Zeng X-M, Ou-Yang J. MicroRNA-155-5p inhibits the invasion and migration of prostate cancer cells by targeting SPOCK1. Oncol Lett. 2020;20(6):353.","journal-title":"Oncol Lett"},{"issue":"9","key":"3006_CR129","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1073\/pnas.1717363115","volume":"115","author":"K Hashimoto","year":"2018","unstructured":"Hashimoto K, Ochi H, Sunamura S, Kosaka N, Mabuchi Y, Fukuda T, et al. Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in the bone metastatic microenvironment via targeting ARHGAP1 and FAM134A. Proc Natl Acad Sci USA. 2018;115(9):2204\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"3006_CR130","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1007\/s12094-016-1564-3","volume":"19","author":"Q Li","year":"2017","unstructured":"Li Q, Lu S, Li X, Hou G, Yan L, Zhang W, et al. Biological function and mechanism of miR-33a in prostate cancer survival and metastasis: via downregulating engrailed-2. Clin Transl Oncol. 2017;19(5):562\u201370.","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"3006_CR131","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13046-019-1059-5","volume":"38","author":"L Zhang","year":"2019","unstructured":"Zhang L, Liao Y, Tang L. MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer. J Exp Clin Cancer Res. 2019;38(1):53.","journal-title":"J Exp Clin Cancer Res"},{"issue":"12","key":"3006_CR132","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.3390\/ijms18122762","volume":"18","author":"LL Fang","year":"2017","unstructured":"Fang LL, Sun BF, Huang LR, Yuan HB, Zhang S, Chen J, et al. Potent inhibition of miR-34b on migration and invasion in metastatic prostate cancer cells by regulating the TGF-\u03b2 pathway. Int J Mol Sci. 2017;18(12):2762.","journal-title":"Int J Mol Sci."},{"issue":"1","key":"3006_CR133","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13045-018-0605-5","volume":"11","author":"C Chen","year":"2018","unstructured":"Chen C, Zhao S, Karnad A, Freeman JW. The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol. 2018;11(1):64.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"3006_CR134","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.apjtm.2016.09.011","volume":"10","author":"Y Yang","year":"2017","unstructured":"Yang Y, Guo JX, Shao ZQ. miR-21 targets and inhibits tumor suppressor gene PTEN to promote prostate cancer cell proliferation and invasion: an experimental study. Asian Pac J Trop Med. 2017;10(1):87\u201391.","journal-title":"Asian Pac J Trop Med"},{"issue":"6","key":"3006_CR135","doi-asserted-by":"publisher","first-page":"371","DOI":"10.5732\/cjc.30.0371","volume":"30","author":"LEB Buscaglia","year":"2011","unstructured":"Buscaglia LEB, Li Y. Apoptosis and the target genes of microRNA-21. Chin J Cancer. 2011;30(6):371\u201380.","journal-title":"Chin J Cancer"},{"issue":"7","key":"3006_CR136","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1158\/1541-7786.MCR-17-0230","volume":"16","author":"B Chakravarthi","year":"2018","unstructured":"Chakravarthi B, Chandrashekar DS, Agarwal S, Balasubramanya SAH, Pathi SS, Goswami MT, et al. miR-34a regulates expression of the stathmin-1 oncoprotein and prostate cancer progression. Mol Cancer Res. 2018;16(7):1125\u201337.","journal-title":"Mol Cancer Res"},{"key":"3006_CR137","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ejca.2020.06.025","volume":"137","author":"T Lange","year":"2020","unstructured":"Lange T, Samatov TR, Galatenko VV, Steffen P, von Kriegstein H, Spethmann T, et al. Xenograft-derived mRNA\/miR and protein interaction networks of systemic dissemination in human prostate cancer. Eur J Cancer. 2020;137:93\u2013107.","journal-title":"Eur J Cancer"},{"issue":"11","key":"3006_CR138","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1038\/nm.1880","volume":"14","author":"D Bonci","year":"2008","unstructured":"Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L, et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med. 2008;14(11):1271\u20137.","journal-title":"Nat Med"},{"issue":"16","key":"3006_CR139","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/pros.23241","volume":"76","author":"W Fu","year":"2016","unstructured":"Fu W, Tao T, Qi M, Wang L, Hu J, Li X, et al. MicroRNA-132\/212 upregulation inhibits TGF-\u03b2-mediated epithelial-mesenchymal transition of prostate cancer cells by targeting SOX4. Prostate. 2016;76(16):1560\u201370.","journal-title":"Prostate"},{"issue":"1","key":"3006_CR140","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12967-020-02644-x","volume":"19","author":"M Parol","year":"2021","unstructured":"Parol M, Gzil A, Bodnar M, Grzanka D. Systematic review and meta-analysis of the prognostic significance of microRNAs related to metastatic and EMT process among prostate cancer patients. J Transl Med. 2021;19(1):28.","journal-title":"J Transl Med"},{"issue":"5","key":"3006_CR141","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.3892\/ol.2015.3645","volume":"10","author":"K Duan","year":"2015","unstructured":"Duan K, Ge YC, Zhang XP, Wu SY, Feng JS, Chen SL, et al. miR-34a inhibits cell proliferation in prostate cancer by downregulation of SIRT1 expression. Oncol Lett. 2015;10(5):3223\u20137.","journal-title":"Oncol Lett"},{"key":"3006_CR142","doi-asserted-by":"publisher","first-page":"e43511","DOI":"10.7554\/eLife.43511","volume":"8","author":"X Yan","year":"2019","unstructured":"Yan X, Tang B, Chen B, Shan Y, Yang H, Iorns E, et al. Replication study: The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. eLife. 2019;8:e43511.","journal-title":"eLife"},{"issue":"36","key":"3006_CR143","doi-asserted-by":"publisher","first-page":"e16705","DOI":"10.1097\/MD.0000000000016705","volume":"98","author":"C-W Bi","year":"2019","unstructured":"Bi C-W, Zhang G-Y, Bai Y, Zhao B, Yang H. Increased expression of miR-153 predicts poor prognosis for patients with prostate cancer. Medicine. 2019;98(36):e16705.","journal-title":"Medicine."},{"issue":"6","key":"3006_CR144","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1002\/pros.22600","volume":"73","author":"Z Wu","year":"2013","unstructured":"Wu Z, He B, He J, Mao X. Upregulation of miR-153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer. Prostate. 2013;73(6):596\u2013604.","journal-title":"Prostate"},{"issue":"3","key":"3006_CR145","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41388-018-0450-6","volume":"38","author":"MD Long","year":"2019","unstructured":"Long MD, Singh PK, Russell JR, Llimos G, Rosario S, Rizvi A, et al. The miR-96 and RAR\u03b3 signaling axis governs androgen signaling and prostate cancer progression. Oncogene. 2019;38(3):421\u201344.","journal-title":"Oncogene"},{"issue":"11","key":"3006_CR146","doi-asserted-by":"publisher","first-page":"e80807","DOI":"10.1371\/journal.pone.0080807","volume":"8","author":"A Fendler","year":"2013","unstructured":"Fendler A, Jung M, Stephan C, Erbersdobler A, Jung K, Yousef GM. The antiapoptotic function of miR-96 in prostate cancer by inhibition of FOXO1. PLoS ONE. 2013;8(11):e80807.","journal-title":"PLoS ONE."},{"issue":"1","key":"3006_CR147","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3892\/etm.2017.4488","volume":"14","author":"Y Chen","year":"2017","unstructured":"Chen Y, Zhang L. Members of the microRNA-200 family are promising therapeutic targets in cancer. Exp Ther Med. 2017;14(1):10\u20137.","journal-title":"Exp Ther Med"},{"issue":"1","key":"3006_CR148","doi-asserted-by":"publisher","first-page":"14270","DOI":"10.1038\/ncomms14270","volume":"8","author":"C Liu","year":"2017","unstructured":"Liu C, Liu R, Zhang D, Deng Q, Liu B, Chao H-P, et al. MicroRNA-141 suppresses prostate cancer stem cells and metastasis by targeting a cohort of pro-metastasis genes. Nat Commun. 2017;8(1):14270.","journal-title":"Nat Commun"},{"issue":"9","key":"3006_CR149","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3390\/cancers10090289","volume":"10","author":"PKB Nagesh","year":"2018","unstructured":"Nagesh PKB, Chowdhury P, Hatami E, Boya VKN, Kashyap VK, Khan S, et al. miRNA-205 nanoformulation sensitizes prostate cancer cells to chemotherapy. Cancers. 2018;10(9):289.","journal-title":"Cancers."},{"issue":"1","key":"3006_CR150","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3892\/ijo.2013.1915","volume":"43","author":"B Verdoodt","year":"2013","unstructured":"Verdoodt B, Neid M, Vogt M, Kuhn V, Liffers ST, Palisaar RJ, et al. MicroRNA-205, a novel regulator of the anti-apoptotic protein Bcl2, is downregulated in prostate cancer. Int J Oncol. 2013;43(1):307\u201314.","journal-title":"Int J Oncol"},{"issue":"4","key":"3006_CR151","first-page":"e218","volume":"183","author":"S Majid","year":"2010","unstructured":"Majid S, Dar A, Saini S, Chen Y, Shahryari V, Liu J, et al. Induction of tumor suppressor genes il24 and il32 by microrna-205 in prostate cancer: 557. J Urol. 2010;183(4):e218\u20139.","journal-title":"J Urol"},{"key":"3006_CR152","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-019-1060-z","volume":"38","author":"R El Bezawy","year":"2019","unstructured":"El Bezawy R, Tinelli S, Tortoreto M, Doldi V, Zuco V, Folini M, et al. miR-205 enhances radiation sensitivity of prostate cancer cells by impairing DNA damage repair through PKC\u03b5 and ZEB1 inhibition. J Exp Clin Cancer Res. 2019;38:1\u201311.","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"3006_CR153","doi-asserted-by":"publisher","first-page":"R81","DOI":"10.1530\/REP-17-0322","volume":"154","author":"C Massillo","year":"2017","unstructured":"Massillo C, Dalton GN, Farr\u00e9 PL, De Luca P, De Siervi A. Implications of microRNA dysregulation in the development of prostate cancer. Reproduction. 2017;154(4):R81\u201397.","journal-title":"Reproduction"},{"issue":"41","key":"3006_CR154","doi-asserted-by":"publisher","first-page":"67597","DOI":"10.18632\/oncotarget.11708","volume":"7","author":"K Sekhon","year":"2016","unstructured":"Sekhon K, Bucay N, Majid S, Dahiya R, Saini S. MicroRNAs and epithelial-mesenchymal transition in prostate cancer. Oncotarget. 2016;7(41):67597\u2013611.","journal-title":"Oncotarget"},{"issue":"7","key":"3006_CR155","doi-asserted-by":"publisher","first-page":"141","DOI":"10.21037\/atm.2019.02.40","volume":"7","author":"J Zhang","year":"2019","unstructured":"Zhang J, Zhang H, Qin Y, Chen C, Yang J, Song N, et al. MicroRNA-200c-3p\/ZEB2 loop plays a crucial role in the tumor progression of prostate carcinoma. Ann Transl Med. 2019;7(7):141.","journal-title":"Ann Transl Med"},{"issue":"12","key":"3006_CR156","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.1172\/JCI86505","volume":"126","author":"C Dallavalle","year":"2016","unstructured":"Dallavalle C, Albino D, Civenni G, Merulla J, Ostano P, Mello-Grand M, et al. MicroRNA-424 impairs ubiquitination to activate STAT3 and promote prostate tumor progression. J Clin Investig. 2016;126(12):4585\u2013602.","journal-title":"J Clin Investig"},{"issue":"1","key":"3006_CR157","first-page":"29","volume":"6","author":"T Jemt","year":"1991","unstructured":"Jemt T, Laney WR, Harris D, Henry PJ, Krogh PH Jr, Polizzi G, et al. Osseointegrated implants for single tooth replacement: a 1-year report from a multicenter prospective study. Int J Oral Maxillofac Implants. 1991;6(1):29\u201336.","journal-title":"Int J Oral Maxillofac Implants"},{"issue":"2","key":"3006_CR158","first-page":"1889","volume":"17","author":"BIN Xu","year":"2019","unstructured":"Xu BIN, Lu X, Zhao Y, Liu C, Huang X, Chen S, et al. MicroRNA-135a induces prostate cancer cell apoptosis via inhibition of STAT6. Oncol Lett. 2019;17(2):1889\u201395.","journal-title":"Oncol Lett"},{"issue":"10","key":"3006_CR159","doi-asserted-by":"publisher","first-page":"14141","DOI":"10.1007\/s13277-016-5196-6","volume":"37","author":"B Xu","year":"2016","unstructured":"Xu B, Tao T, Wang Y, Fang F, Huang Y, Chen S, et al. hsa-miR-135a-1 inhibits prostate cancer cell growth and migration by targeting EGFR. Tumor Biology. 2016;37(10):14141\u201351.","journal-title":"Tumor Biology"},{"issue":"1","key":"3006_CR160","first-page":"57","volume":"41","author":"Y Tang","year":"2019","unstructured":"Tang Y, Wu B, Huang S, Peng X, Li X, Huang X, et al. Downregulation of miR-505-3p predicts poor bone metastasis-free survival in prostate cancer. Oncol Rep. 2019;41(1):57\u201366.","journal-title":"Oncol Rep"},{"key":"3006_CR161","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.biopha.2018.05.041","volume":"104","author":"W Jin","year":"2018","unstructured":"Jin W, Chen F, Wang K, Song Y, Fei X, Wu B. miR-15a\/miR-16 cluster inhibits invasion of prostate cancer cells by suppressing TGF-\u03b2 signaling pathway. Biomed Pharmacother. 2018;104:637\u201344.","journal-title":"Biomed Pharmacother"},{"key":"3006_CR162","doi-asserted-by":"publisher","first-page":"100857","DOI":"10.1016\/j.genrep.2020.100857","volume":"21","author":"MJ Ramaiah","year":"2020","unstructured":"Ramaiah MJ. Corrigendum to \u201cFunctions and epigenetic aspects of miR-15\/16: possible future cancer therapeutics\u201d [Gene Rep. 12 (2018) 14\u2013164]. Gene Rep. 2020;21:100857.","journal-title":"Gene Rep"},{"issue":"12","key":"3006_CR163","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0083991","volume":"8","author":"LV Williams","year":"2013","unstructured":"Williams LV, Veliceasa D, Vinokour E, Volpert OV. miR-200b inhibits prostate cancer EMT, growth and metastasis. PLoS ONE. 2013;8(12): e83991.","journal-title":"PLoS ONE"},{"issue":"44","key":"3006_CR164","doi-asserted-by":"publisher","first-page":"5183","DOI":"10.1038\/onc.2013.461","volume":"33","author":"J Kim","year":"2014","unstructured":"Kim J, Wu L, Zhao JC, Jin HJ, Yu J. TMPRSS2-ERG gene fusions induce prostate tumorigenesis by modulating microRNA miR-200c. Oncogene. 2014;33(44):5183\u201392.","journal-title":"Oncogene"},{"issue":"10","key":"3006_CR165","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1038\/bjc.2014.181","volume":"110","author":"HM Lin","year":"2014","unstructured":"Lin HM, Castillo L, Mahon KL, Chiam K, Lee BY, Nguyen Q, et al. Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. Br J Cancer. 2014;110(10):2462\u201371.","journal-title":"Br J Cancer"},{"issue":"2","key":"3006_CR166","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.18632\/oncotarget.23026","volume":"9","author":"F Fu","year":"2018","unstructured":"Fu F, Wan X, Wang D, Kong Z, Zhang Y, Huang W, et al. MicroRNA-19a acts as a prognostic marker and promotes prostate cancer progression via inhibiting VPS37A expression. Oncotarget. 2018;9(2):1931\u201343.","journal-title":"Oncotarget"},{"issue":"13","key":"3006_CR167","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/j.febslet.2015.04.037","volume":"589","author":"K Lu","year":"2015","unstructured":"Lu K, Liu C, Tao T, Zhang X, Zhang L, Sun C, et al. MicroRNA-19a regulates proliferation and apoptosis of castration-resistant prostate cancer cells by targeting BTG1. FEBS Lett. 2015;589(13):1485\u201390.","journal-title":"FEBS Lett"},{"issue":"1","key":"3006_CR168","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1158\/1078-0432.CCR-12-2952","volume":"19","author":"S Majid","year":"2013","unstructured":"Majid S, Dar AA, Saini S, Shahryari V, Arora S, Zaman MS, et al. miRNA-34b inhibits prostate cancer through demethylation, active chromatin modifications, and AKT pathways. Clin Cancer Res. 2013;19(1):73\u201384.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"3006_CR169","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1038\/cdd.2017.69","volume":"24","author":"N Bucay","year":"2017","unstructured":"Bucay N, Bhagirath D, Sekhon K, Yang T, Fukuhara S, Majid S, et al. A novel microRNA regulator of prostate cancer epithelial-mesenchymal transition. Cell Death Differ. 2017;24(7):1263\u201374.","journal-title":"Cell Death Differ"},{"issue":"6","key":"3006_CR170","first-page":"9051","volume":"15","author":"Y Hua","year":"2018","unstructured":"Hua Y, Liang C, Miao C, Wang S, Su S, Shao P, et al. MicroRNA-126 inhibits proliferation and metastasis in prostate cancer via regulation of ADAM9. Oncol Lett. 2018;15(6):9051\u201360.","journal-title":"Oncol Lett"},{"issue":"2","key":"3006_CR171","doi-asserted-by":"publisher","first-page":"227","DOI":"10.4161\/cc.26984","volume":"13","author":"H Lewis","year":"2014","unstructured":"Lewis H, Lance R, Troyer D, Beydoun H, Hadley M, Orians J, et al. MiR-888 is an expressed prostatic secretionsderived microRNA that promotes prostate cell growth and migration. Cell Cycle. 2014;13(2):227\u201339.","journal-title":"Cell Cycle"},{"issue":"10","key":"3006_CR172","doi-asserted-by":"publisher","first-page":"16581","DOI":"10.18632\/oncotarget.15016","volume":"8","author":"Y Hashimoto","year":"2017","unstructured":"Hashimoto Y, Shiina M, Kato T, Yamamura S, Tanaka Y, Majid S, et al. The role of miR-24 as a race related genetic factor in prostate cancer. Oncotarget. 2017;8(10):16581\u201393.","journal-title":"Oncotarget"},{"issue":"4","key":"3006_CR173","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.3892\/ijo.2013.1825","volume":"42","author":"D Ren","year":"2013","unstructured":"Ren D, Wang M, Guo W, Zhao X, Tu X, Huang S, et al. Wild-type p53 suppresses the epithelial-mesenchymal transition and stemness in PC-3 prostate cancer cells by modulating miR-145. Int J Oncol. 2013;42(4):1473\u201381.","journal-title":"Int J Oncol"},{"issue":"9","key":"3006_CR174","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1158\/1078-0432.CCR-13-1588","volume":"20","author":"X Li","year":"2014","unstructured":"Li X, Wan X, Chen H, Yang S, Liu Y, Mo W, et al. Identification of miR-133b and RB1CC1 as independent predictors for biochemical recurrence and potential therapeutic targets for prostate cancer. Clin Cancer Res. 2014;20(9):2312\u201325.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"3006_CR175","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1002\/jcb.24502","volume":"114","author":"W Guo","year":"2013","unstructured":"Guo W, Ren D, Chen X, Tu X, Huang S, Wang M, et al. HEF1 promotes epithelial mesenchymal transition and bone invasion in prostate cancer under the regulation of microRNA-145. J Cell Biochem. 2013;114(7):1606\u201315.","journal-title":"J Cell Biochem"},{"issue":"4","key":"3006_CR176","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/S1535-6108(04)00079-0","volume":"5","author":"DM Brown","year":"2004","unstructured":"Brown DM, Ruoslahti E. Metadherin, a cell surface protein in breast tumors that mediates lung metastasis. Cancer Cell. 2004;5(4):365\u201374.","journal-title":"Cancer Cell"},{"issue":"6","key":"3006_CR177","first-page":"1955","volume":"54","author":"D Pan","year":"2019","unstructured":"Pan D, Jia Z, Li W, Dou Z. The targeting of MTDH by miR-145-5p or miR-145-3p is associated with prognosis and regulates the growth and metastasis of prostate cancer cells. Int J Oncol. 2019;54(6):1955\u201368.","journal-title":"Int J Oncol"},{"issue":"4","key":"3006_CR178","first-page":"5291","volume":"16","author":"W Gao","year":"2018","unstructured":"Gao W, Hong Z, Huang H, Zhu A, Lin S, Cheng C, et al. miR-27a in serum acts as biomarker for prostate cancer detection and promotes cell proliferation by targeting Sprouty2. Oncol Lett. 2018;16(4):5291\u20138.","journal-title":"Oncol Lett"},{"key":"3006_CR179","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.biocel.2016.08.043","volume":"79","author":"X Wan","year":"2016","unstructured":"Wan X, Huang W, Yang S, Zhang Y, Zhang P, Kong Z, et al. Androgen-induced miR-27A acted as a tumor suppressor by targeting MAP2K4 and mediated prostate cancer progression. Int J Biochem Cell Biol. 2016;79:249\u201360.","journal-title":"Int J Biochem Cell Biol"},{"issue":"5","key":"3006_CR180","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/pros.21270","volume":"71","author":"XB Shi","year":"2011","unstructured":"Shi XB, Xue L, Ma AH, Tepper CG, Kung HJ, White RWD. MiR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes. Prostate. 2011;71(5):538\u201349.","journal-title":"Prostate"},{"issue":"14_supplement","key":"3006_CR181","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1158\/1538-7445.AM2016-1091","volume":"76","author":"ST Aherne","year":"2016","unstructured":"Aherne ST, O\u2019Neill F, Madden SF, Clynes M, Lynch CC. miR-125 family of miRNAs mediates prostate cancer cell proliferation and migration. Cancer Res. 2016;76(14_supplement):1091.","journal-title":"Cancer Res."},{"issue":"5","key":"3006_CR182","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.3892\/ijmm.2015.2355","volume":"36","author":"Q Fu","year":"2015","unstructured":"Fu Q, Liu X, Liu Y, Yang J, Lv G, Dong S. MicroRNA-335 and -543 suppress bone metastasis in prostate cancer via targeting endothelial nitric oxide synthase. Int J Mol Med. 2015;36(5):1417\u201325.","journal-title":"Int J Mol Med"},{"key":"3006_CR183","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.2147\/OTT.S102862","volume":"9","author":"K Han","year":"2016","unstructured":"Han K, Meng W, Zhang JJ, Zhou Y, Wang YL, Su Y, et al. Luteolin inhibited proliferation and induced apoptosis of prostate cancer cells through miR-301. Onco Targets Ther. 2016;9:3085\u201394.","journal-title":"Onco Targets Ther"},{"issue":"3","key":"3006_CR184","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/ijc.28707","volume":"135","author":"ZY Lin","year":"2014","unstructured":"Lin ZY, Huang YQ, Zhang YQ, Han ZD, He HC, Ling XH, et al. MicroRNA-224 inhibits progression of human prostate cancer by downregulating TRIB1. Int J Cancer. 2014;135(3):541\u201350.","journal-title":"Int J Cancer"},{"issue":"10","key":"3006_CR185","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1016\/j.febslet.2014.04.020","volume":"588","author":"Y Goto","year":"2014","unstructured":"Goto Y, Nishikawa R, Kojima S, Chiyomaru T, Enokida H, Inoguchi S, et al. Tumour-suppressive microRNA-224 inhibits cancer cell migration and invasion via targeting oncogenic TPD52 in prostate cancer. FEBS Lett. 2014;588(10):1973\u201382.","journal-title":"FEBS Lett"},{"issue":"16","key":"3006_CR186","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1200\/JCO.2006.09.0795","volume":"25","author":"MJ Birrer","year":"2007","unstructured":"Birrer MJ, Johnson ME, Hao K, Wong KK, Park DC, Bell A, et al. Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. J Clin Oncol. 2007;25(16):2281\u20137.","journal-title":"J Clin Oncol"},{"key":"3006_CR187","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/1476-4598-13-250","volume":"13","author":"S Rajendiran","year":"2014","unstructured":"Rajendiran S, Parwani AV, Hare RJ, Dasgupta S, Roby RK, Vishwanatha JK. MicroRNA-940 suppresses prostate cancer migration and invasion by regulating MIEN1. Mol Cancer. 2014;13:250.","journal-title":"Mol Cancer"},{"key":"3006_CR188","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.628094","volume":"11","author":"S Rajendiran","year":"2021","unstructured":"Rajendiran S, Maji S, Haddad A, Lotan Y, Nandy RR, Vishwanatha JK, et al. MicroRNA-940 as a potential serum biomarker for prostate cancer. Front Oncol. 2021;11: 628094.","journal-title":"Front Oncol"},{"issue":"10","key":"3006_CR189","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/bjc.2016.95","volume":"114","author":"Y Goto","year":"2016","unstructured":"Goto Y, Kojima S, Kurozumi A, Kato M, Okato A, Matsushita R, et al. Regulation of E3 ubiquitin ligase-1 (WWP1) by microRNA-452 inhibits cancer cell migration and invasion in prostate cancer. Br J Cancer. 2016;114(10):1135\u201344.","journal-title":"Br J Cancer"},{"issue":"11","key":"3006_CR190","doi-asserted-by":"publisher","first-page":"e78023","DOI":"10.1371\/journal.pone.0078023","volume":"8","author":"S Arora","year":"2013","unstructured":"Arora S, Saini S, Fukuhara S, Majid S, Shahryari V, Yamamura S, et al. MicroRNA-4723 inhibits prostate cancer growth through inactivation of the abelson family of nonreceptor protein tyrosine kinases. PLoS ONE. 2013;8(11):e78023.","journal-title":"PLoS ONE."},{"issue":"7","key":"3006_CR191","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0159601","volume":"11","author":"SJ Seashols-Williams","year":"2016","unstructured":"Seashols-Williams SJ, Budd W, Clark GC, Wu Q, Daniel R, Dragoescu E, et al. miR-9 acts as an oncomir in prostate cancer through multiple pathways that drive tumour progression and metastasis. PLoS ONE. 2016;11(7): e0159601.","journal-title":"PLoS ONE"},{"issue":"21","key":"3006_CR192","first-page":"4835","volume":"21","author":"C Zhiping","year":"2017","unstructured":"Zhiping C, Shijun T, Linhui W, Yapei W, Lianxi Q, Qiang D. MiR-181a promotes epithelial to mesenchymal transition of prostate cancer cells by targeting TGIF2. Eur Rev Med Pharmacol Sci. 2017;21(21):4835\u201343.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"4","key":"3006_CR193","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.clgc.2015.01.003","volume":"13","author":"Y-L Wang","year":"2015","unstructured":"Wang Y-L, Wu S, Jiang B, Yin F-F, Zheng S-S, Hou S-C. Role of microRNAs in prostate cancer pathogenesis. Clin Genitourin Cancer. 2015;13(4):261\u201370.","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"3006_CR194","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.3892\/mmr.2014.2782","volume":"11","author":"Y Ouyang","year":"2015","unstructured":"Ouyang Y, Gao P, Zhu B, Chen X, Lin F, Wang X, et al. Downregulation of microRNA-429 inhibits cell proliferation by targeting p27Kip1 in human prostate cancer cells. Mol Med Rep. 2015;11(2):1435\u201341.","journal-title":"Mol Med Rep"},{"issue":"1","key":"3006_CR195","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12943-017-0688-6","volume":"16","author":"D Ren","year":"2017","unstructured":"Ren D, Yang Q, Dai Y, Guo W, Du H, Song L, et al. Oncogenic miR-210-3p promotes prostate cancer cell EMT and bone metastasis via NF-\u03baB signaling pathway. Mol Cancer. 2017;16(1):117.","journal-title":"Mol Cancer"},{"issue":"44","key":"3006_CR196","doi-asserted-by":"publisher","first-page":"5173","DOI":"10.1038\/onc.2013.451","volume":"33","author":"A Formosa","year":"2013","unstructured":"Formosa A, Markert EK, Lena AM, Italiano D, Finazzi-Agro E, Levine AJ, et al. MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells. Oncogene. 2013;33(44):5173\u201382.","journal-title":"Oncogene."},{"key":"3006_CR197","doi-asserted-by":"crossref","unstructured":"Zhu C, Shao P, Bao M, Li P, Zhou H, Cai H, et al., editors. miR-154 inhibits prostate cancer cell proliferation by targeting CCND2. In: Urologic oncology: seminars and original investigations; 2014: Elsevier.","DOI":"10.1016\/j.urolonc.2012.11.013"},{"issue":"1\u20132","key":"3006_CR198","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11010-013-1628-4","volume":"379","author":"C Zhu","year":"2013","unstructured":"Zhu C, Li J, Cheng G, Zhou H, Tao L, Cai H, et al. MiR-154 inhibits EMT by targeting HMGA2 in prostate cancer cells. Mol Cell Biochem. 2013;379(1\u20132):69\u201375.","journal-title":"Mol Cell Biochem"},{"issue":"3","key":"3006_CR199","doi-asserted-by":"publisher","first-page":"e33729","DOI":"10.1371\/journal.pone.0033729","volume":"7","author":"D Kong","year":"2012","unstructured":"Kong D, Heath E, Chen W, Cher ML, Powell I, Heilbrun L, et al. Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM. PLoS ONE. 2012;7(3):e33729.","journal-title":"PLoS ONE"},{"issue":"13","key":"3006_CR200","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1158\/0008-5472.CAN-11-3864","volume":"72","author":"C Liu","year":"2012","unstructured":"Liu C, Kelnar K, Vlassov AV, Brown D, Wang J, Tang DG. Distinct microRNA expression profiles in prostate cancer stem\/progenitor cells and tumor-suppressive functions of let-7. Can Res. 2012;72(13):3393\u2013404.","journal-title":"Can Res"},{"issue":"1","key":"3006_CR201","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/1756-9966-30-87","volume":"30","author":"RS Wong","year":"2011","unstructured":"Wong RS. Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res. 2011;30(1):87.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"3006_CR202","first-page":"50","volume":"89","author":"V Pileczki","year":"2016","unstructured":"Pileczki V, Cojocneanu-Petric R, Maralani M, Neagoe IB, Sandulescu R. MicroRNAs as regulators of apoptosis mechanisms in cancer. Clujul Med. 2016;89(1):50\u20135.","journal-title":"Clujul Med"},{"key":"3006_CR203","doi-asserted-by":"publisher","first-page":"359","DOI":"10.12659\/MSM.899719","volume":"23","author":"Z Ma","year":"2017","unstructured":"Ma Z, Luo Y, Qiu M. miR-143 induces the apoptosis of prostate cancer LNCap cells by suppressing Bcl-2 expression. Med Sci Monit. 2017;23:359\u201365.","journal-title":"Med Sci Monit"},{"issue":"3","key":"3006_CR204","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.bbrc.2014.12.026","volume":"456","author":"G Han","year":"2015","unstructured":"Han G, Fan M, Zhang X. microRNA-218 inhibits prostate cancer cell growth and promotes apoptosis by repressing TPD52 expression. Biochem Biophys Res Commun. 2015;456(3):804\u20139.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"3006_CR205","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.15","volume":"8","author":"M Colden","year":"2017","unstructured":"Colden M, Dar AA, Saini S, Dahiya PV, Shahryari V, Yamamura S, et al. MicroRNA-466 inhibits tumor growth and bone metastasis in prostate cancer by direct regulation of osteogenic transcription factor RUNX2. Cell Death Dis. 2017;8(1): e2572.","journal-title":"Cell Death Dis"},{"issue":"4","key":"3006_CR206","first-page":"4775","volume":"15","author":"D Zhu","year":"2018","unstructured":"Zhu D, Gao W, Zhang Z. MicroRNA-1180 is associated with growth and apoptosis in prostate cancer via TNF receptor associated factor 1 expression regulation and nuclear factor-\u03baB signaling pathway activation. Oncol Lett. 2018;15(4):4775\u201380.","journal-title":"Oncol Lett"},{"issue":"10","key":"3006_CR207","doi-asserted-by":"publisher","first-page":"6037","DOI":"10.1074\/jbc.M114.632125","volume":"290","author":"CH Yang","year":"2015","unstructured":"Yang CH, Pfeffer SR, Sims M, Yue J, Wang Y, Linga VG, et al. The oncogenic microRNA-21 inhibits the tumor suppressive activity of FBXO11 to promote tumorigenesis. J Biol Chem. 2015;290(10):6037\u201346.","journal-title":"J Biol Chem"},{"issue":"13","key":"3006_CR208","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1002\/pros.23201","volume":"76","author":"SM Lynch","year":"2016","unstructured":"Lynch SM, O\u2019Neill KM, McKenna MM, Walsh CP, McKenna DJ. Regulation of miR-200c and miR-141 by methylation in prostate cancer. Prostate. 2016;76(13):1146\u201359.","journal-title":"Prostate"},{"issue":"1","key":"3006_CR209","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13148-015-0076-2","volume":"7","author":"P Costa-Pinheiro","year":"2015","unstructured":"Costa-Pinheiro P, Ramalho-Carvalho J, Vieira FQ, Torres-Ferreira J, Oliveira J, Gon\u00e7alves CS, et al. MicroRNA-375 plays a dual role in prostate carcinogenesis. Clin Epigenetics. 2015;7(1):42.","journal-title":"Clin Epigenetics"},{"issue":"9","key":"3006_CR210","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1158\/0008-5472.CAN-13-1606","volume":"74","author":"B Kneitz","year":"2014","unstructured":"Kneitz B, Krebs M, Kalogirou C, Schubert M, Joniau S, van Poppel H, et al. Survival in patients with high-risk prostate cancer is predicted by miR-221, which regulates proliferation, apoptosis, and invasion of prostate cancer cells by inhibiting IRF2 and SOCS3. Cancer Res. 2014;74(9):2591\u2013603.","journal-title":"Cancer Res"},{"issue":"2","key":"3006_CR211","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.gene.2015.07.017","volume":"572","author":"L Wang","year":"2015","unstructured":"Wang L, Liu C, Li C, Xue J, Zhao S, Zhan P, et al. Effects of microRNA-221\/222 on cell proliferation and apoptosis in prostate cancer cells. Gene. 2015;572(2):252\u20138.","journal-title":"Gene"},{"issue":"4","key":"3006_CR212","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/PPO.0000000000000138","volume":"21","author":"DR Bielenberg","year":"2015","unstructured":"Bielenberg DR, Zetter BR. The contribution of angiogenesis to the process of metastasis. Cancer J. 2015;21(4):267\u201373.","journal-title":"Cancer J"},{"issue":"3","key":"3006_CR213","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.ygyno.2021.03.020","volume":"161","author":"N Rahimian","year":"2021","unstructured":"Rahimian N, Razavi ZS, Aslanbeigi F, Mirkhabbaz AM, Piroozmand H, Shahrzad MK, et al. Non-coding RNAs related to angiogenesis in gynecological cancer. Gynecol Oncol. 2021;161(3):896\u2013912.","journal-title":"Gynecol Oncol"},{"issue":"9","key":"3006_CR214","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2020.153082","volume":"216","author":"R Mardani","year":"2020","unstructured":"Mardani R, Hamblin MR, Taghizadeh M, Banafshe HR, Nejati M, Mokhtari M, et al. Nanomicellar\u2013curcumin exerts its therapeutic effects via affecting angiogenesis, apoptosis, and T cells in a mouse model of melanoma lung metastasis. Pathol Res Pract. 2020;216(9): 153082.","journal-title":"Pathol Res Pract"},{"issue":"4","key":"3006_CR215","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1002\/jcp.26049","volume":"233","author":"M Mashreghi","year":"2018","unstructured":"Mashreghi M, Azarpara H, Bazaz MR, Jafari A, Masoudifar A, Mirzaei H, et al. Angiogenesis biomarkers and their targeting ligands as potential targets for tumor angiogenesis. J Cell Physiol. 2018;233(4):2949\u201365.","journal-title":"J Cell Physiol"},{"key":"3006_CR216","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.biopha.2017.01.161","volume":"89","author":"B Rashidi","year":"2017","unstructured":"Rashidi B, Malekzadeh M, Goodarzi M, Masoudifar A, Mirzaei H. Green tea and its anti-angiogenesis effects. Biomed Pharmacother. 2017;89:949\u201356.","journal-title":"Biomed Pharmacother"},{"issue":"48","key":"3006_CR217","doi-asserted-by":"publisher","first-page":"83523","DOI":"10.18632\/oncotarget.18315","volume":"8","author":"J Zhong","year":"2017","unstructured":"Zhong J, Huang R, Su Z, Zhang M, Xu M, Gong J, et al. Downregulation of miR-199a-5p promotes prostate adenocarcinoma progression through loss of its inhibition of HIF-1\u03b1. Oncotarget. 2017;8(48):83523\u201338.","journal-title":"Oncotarget"},{"issue":"28","key":"3006_CR218","doi-asserted-by":"publisher","first-page":"44350","DOI":"10.18632\/oncotarget.10051","volume":"7","author":"E Terzuoli","year":"2016","unstructured":"Terzuoli E, Donnini S, Finetti F, Nesi G, Villari D, Hanaka H, et al. Linking microsomal prostaglandin E Synthase-1\/PGE-2 pathway with miR-15a and\u2212 186 expression: novel mechanism of VEGF modulation in prostate cancer. Oncotarget. 2016;7(28):44350.","journal-title":"Oncotarget"},{"issue":"30","key":"3006_CR219","doi-asserted-by":"publisher","first-page":"47444","DOI":"10.18632\/oncotarget.10165","volume":"7","author":"Y Wang","year":"2016","unstructured":"Wang Y, Shao N, Mao X, Zhu M, Fan W, Shen Z, et al. MiR-4638-5p inhibits castration resistance of prostate cancer through repressing Kidins220 expression and PI3K\/AKT pathway activity. Oncotarget. 2016;7(30):47444.","journal-title":"Oncotarget"},{"issue":"1","key":"3006_CR220","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1021\/acs.molpharmaceut.8b01074","volume":"16","author":"W Jiang","year":"2018","unstructured":"Jiang W, Gao Y, Wang Z, Gong C, Hu C, Ding X, et al. Codelivery of miR-4638\u20135p and docetaxel based on redox-sensitive polypeptide micelles as an improved strategy for the treatment of castration-resistant prostate cancer. Mol Pharm. 2018;16(1):437\u201347.","journal-title":"Mol Pharm"},{"issue":"1","key":"3006_CR221","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s12094-019-02217-5","volume":"22","author":"HQ Mu","year":"2020","unstructured":"Mu HQ, He YH, Wang SB, Yang S, Wang YJ, Nan CJ, et al. MiR-130b\/TNF-\u03b1\/NF-\u03baB\/VEGFA loop inhibits prostate cancer angiogenesis. Clin Transl Oncol. 2020;22(1):111\u201321.","journal-title":"Clin Transl Oncol"},{"issue":"6","key":"3006_CR222","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nm0603-677","volume":"9","author":"CW Pugh","year":"2003","unstructured":"Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: Role of the HIF system. Nat Med. 2003;9(6):677\u201384.","journal-title":"Nat Med"},{"issue":"1","key":"3006_CR223","doi-asserted-by":"publisher","first-page":"19","DOI":"10.7150\/jca.9591","volume":"6","author":"EJ Sohn","year":"2015","unstructured":"Sohn EJ, Won G, Lee J, Lee S, Kim SH. Upregulation of miRNA3195 and miRNA374b mediates the anti-angiogenic properties of melatonin in hypoxic PC-3 prostate cancer cells. J Cancer. 2015;6(1):19\u201328.","journal-title":"J Cancer"},{"issue":"63","key":"3006_CR224","doi-asserted-by":"publisher","first-page":"107157","DOI":"10.18632\/oncotarget.22362","volume":"8","author":"XB Niu","year":"2017","unstructured":"Niu XB, Fu GB, Wang L, Ge X, Liu WT, Wen YY, et al. Insulin-like growth factor-I induces chemoresistence to docetaxel by inhibiting miR-143 in human prostate cancer. Oncotarget. 2017;8(63):107157\u201366.","journal-title":"Oncotarget"},{"issue":"30","key":"3006_CR225","doi-asserted-by":"publisher","first-page":"47444","DOI":"10.18632\/oncotarget.10165","volume":"7","author":"Y Wang","year":"2016","unstructured":"Wang Y, Shao N, Mao X, Zhu M, Fan W, Shen Z, et al. MiR-4638-5p inhibits castration resistance of prostate cancer through repressing kidins220 expression and PI3K\/AKT pathway activity. Oncotarget. 2016;7(30):47444\u201364.","journal-title":"Oncotarget"},{"issue":"11","key":"3006_CR226","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1002\/pros.22466","volume":"72","author":"B Xu","year":"2012","unstructured":"Xu B, Wang N, Wang X, Tong N, Shao N, Tao J, et al. MiR-146a suppresses tumor growth and progression by targeting EGFR pathway and in a p-ERK-dependent manner in castration-resistant prostate cancer. Prostate. 2012;72(11):1171\u20138.","journal-title":"Prostate"},{"issue":"12","key":"3006_CR227","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1111\/cas.12548","volume":"105","author":"H Ji","year":"2014","unstructured":"Ji H, Li Y, Jiang F, Wang X, Zhang J, Shen J, et al. Inhibition of transforming growth factor beta\/SMAD signal by MiR-155 is involved in arsenic trioxide-induced anti-angiogenesis in prostate cancer. Cancer Sci. 2014;105(12):1541\u20139.","journal-title":"Cancer Sci"},{"issue":"4","key":"3006_CR228","first-page":"1658","volume":"39","author":"C Cai","year":"2018","unstructured":"Cai C, He H, Duan X, Wu W, Mai Z, Zhang T, et al. miR-195 inhibits cell proliferation and angiogenesis in human prostate cancer by downregulating PRR11 expression Corrigendum in\/10.3892\/or.2023.8507. Oncol Rep. 2018;39(4):1658\u201370.","journal-title":"Oncol Rep"},{"issue":"5","key":"3006_CR229","doi-asserted-by":"publisher","first-page":"8162","DOI":"10.18632\/oncotarget.14131","volume":"8","author":"B Guan","year":"2017","unstructured":"Guan B, Wu K, Zeng J, Xu S, Mu L, Gao Y, et al. Tumor-suppressive microRNA-218 inhibits tumor angiogenesis via targeting the mTOR component RICTOR in prostate cancer. Oncotarget. 2017;8(5):8162\u201372.","journal-title":"Oncotarget"},{"issue":"3","key":"3006_CR230","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/iub.1720","volume":"70","author":"X Tian","year":"2018","unstructured":"Tian X, Tao F, Zhang B, Dong JT, Zhang Z. The miR-203\/SNAI2 axis regulates prostate tumor growth, migration, angiogenesis and stemness potentially by modulating GSK-3\u03b2\/\u03b2-CATENIN signal pathway. IUBMB Life. 2018;70(3):224\u201336.","journal-title":"IUBMB Life"},{"key":"3006_CR231","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-020-07472-2","volume":"20","author":"Y Meng","year":"2020","unstructured":"Meng Y, Hu X, Li S, Zeng X, Qiu L, Wei M, et al. miR-203 inhibits cell proliferation and ERK pathway in prostate cancer by targeting IRS-1. BMC Cancer. 2020;20:1\u201314.","journal-title":"BMC Cancer"},{"issue":"33","key":"3006_CR232","doi-asserted-by":"publisher","first-page":"34446","DOI":"10.18632\/oncotarget.5920","volume":"6","author":"M Ramalinga","year":"2015","unstructured":"Ramalinga M, Roy A, Srivastava A, Bhattarai A, Harish V, Suy S, et al. MicroRNA-212 negatively regulates starvation induced autophagy in prostate cancer cells by inhibiting SIRT1 and is a modulator of angiogenesis and cellular senescence. Oncotarget. 2015;6(33):34446\u201357.","journal-title":"Oncotarget"},{"issue":"28","key":"3006_CR233","doi-asserted-by":"publisher","first-page":"44350","DOI":"10.18632\/oncotarget.10051","volume":"7","author":"E Terzuoli","year":"2016","unstructured":"Terzuoli E, Donnini S, Finetti F, Nesi G, Villari D, Hanaka H, et al. Linking microsomal prostaglandin E Synthase-1\/PGE-2 pathway with miR-15a and -186 expression: Novel mechanism of VEGF modulation in prostate cancer. Oncotarget. 2016;7(28):44350\u201364.","journal-title":"Oncotarget"},{"key":"3006_CR234","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12894-020-00617-2","volume":"20","author":"Y Li","year":"2020","unstructured":"Li Y, Zhong W, Zhu M, Li M, Yang Z. miR-185 inhibits prostate cancer angiogenesis induced by the nodal\/ALK4 pathway. BMC Urol. 2020;20:1\u201311.","journal-title":"BMC Urol"},{"key":"3006_CR235","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-019-0977-9","volume":"19","author":"Z Jiang","year":"2019","unstructured":"Jiang Z, Zhang Y, Chen X, Wu P, Chen D. Inactivation of the Wnt\/\u03b2-catenin signaling pathway underlies inhibitory role of microRNA-129-5p in epithelial\u2013mesenchymal transition and angiogenesis of prostate cancer by targeting ZIC2. Cancer Cell Int. 2019;19:1\u201315.","journal-title":"Cancer Cell Int"},{"issue":"03","key":"3006_CR236","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1055\/a-1977-8848","volume":"73","author":"FA Al-Marzook","year":"2023","unstructured":"Al-Marzook FA, Hassan DM, Alghazal MW, Kadheem RAA, Jalil AT, Saleh MM. MicroRNA-32 suppression: its effects on prostate cancer cells\u2019 capability to proliferate and migrate. Drug Res. 2023;73(03):170\u20134.","journal-title":"Drug Res"},{"issue":"1","key":"3006_CR237","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13046-021-02233-w","volume":"41","author":"C Ferri","year":"2022","unstructured":"Ferri C, Di Biase A, Bocchetti M, Zappavigna S, Wagner S, Le Vu P, et al. MiR-423-5p prevents MALAT1-mediated proliferation and metastasis in prostate cancer. J Exp Clin Cancer Res. 2022;41(1):20.","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"3006_CR238","doi-asserted-by":"publisher","first-page":"e19139","DOI":"10.1371\/journal.pone.0019139","volume":"6","author":"LZ Liu","year":"2011","unstructured":"Liu LZ, Li C, Chen Q, Jing Y, Carpenter R, Jiang Y, et al. Mir-21 induced angiogenesis through AKT and ERK activation and HIF-1\u03b1 expression. PLoS ONE. 2011;6(4):e19139.","journal-title":"PLoS ONE."},{"key":"3006_CR239","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-017-0615-x","volume":"16","author":"Z-Y Lin","year":"2017","unstructured":"Lin Z-Y, Chen G, Zhang Y-Q, He H-C, Liang Y-X, Ye J-H, et al. MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1\/c-JUN\/VEGFA pathway and predicts aggressive outcome in prostate cancer. Mol Cancer. 2017;16:1\u201314.","journal-title":"Mol Cancer"},{"key":"3006_CR240","doi-asserted-by":"publisher","first-page":"12495","DOI":"10.1038\/srep12495","volume":"5","author":"Y Li","year":"2015","unstructured":"Li Y, Zhang D, Wang X, Yao X, Ye C, Zhang S, et al. Hypoxia-inducible MIR-182 enhances HIF1\u03b1 signaling via targeting PHD2 and FIH1 in prostate cancer. Sci Rep. 2015;5:12495.","journal-title":"Sci Rep"},{"issue":"3","key":"3006_CR241","doi-asserted-by":"publisher","first-page":"670","DOI":"10.3390\/jcm9030670","volume":"9","author":"M Krebs","year":"2020","unstructured":"Krebs M, Solimando AG, Kalogirou C, Marquardt A, Frank T, Sokolakis I, et al. Mir-221-3p regulates vegfr2 expression in high- risk prostate cancer and represents an escape mechanism from sunitinib in vitro. J Clin Med. 2020;9(3):670.","journal-title":"J Clin Med"},{"issue":"1\u20132","key":"3006_CR242","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s11010-010-0700-6","volume":"350","author":"B Xu","year":"2011","unstructured":"Xu B, Niu X, Zhang X, Tao J, Wu D, Wang Z, et al. miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS. Mol Cell Biochem. 2011;350(1\u20132):207\u201313.","journal-title":"Mol Cell Biochem"},{"issue":"8","key":"3006_CR243","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0134366","volume":"10","author":"B Dong","year":"2015","unstructured":"Dong B, Shi Z, Wang J, Wu J, Yang Z, Fang K. IL-6 Inhibits the Targeted Modulation of PDCD4 by miR-21 in Prostate Cancer. PLoS ONE. 2015;10(8): e0134366.","journal-title":"PLoS ONE"},{"issue":"7","key":"3006_CR244","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/aps.2010.48","volume":"31","author":"GH Shi","year":"2010","unstructured":"Shi GH, Ye DW, Yao XD, Zhang SL, Dai B, Zhang HL, et al. Involvement of microRNA-21 in mediating chemo-resistance to docetaxel in androgen-independent prostate cancer PC3 cells. Acta Pharmacol Sin. 2010;31(7):867\u201373.","journal-title":"Acta Pharmacol Sin"},{"key":"3006_CR245","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.gene.2018.03.013","volume":"658","author":"Q Feng","year":"2018","unstructured":"Feng Q, He P, Wang Y. MicroRNA-223-3p regulates cell chemo-sensitivity by targeting FOXO3 in prostatic cancer. Gene. 2018;658:152\u20138.","journal-title":"Gene"},{"key":"3006_CR246","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.biopha.2018.01.088","volume":"99","author":"X Ma","year":"2018","unstructured":"Ma X, Zou L, Li X, Chen Z, Lin Q, Wu X. MicroRNA-195 regulates docetaxel resistance by targeting clusterin in prostate cancer. Biomed Pharmacother. 2018;99:445\u201350.","journal-title":"Biomed Pharmacother"},{"issue":"12","key":"3006_CR247","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2010.85","volume":"1","author":"N Bhatnagar","year":"2010","unstructured":"Bhatnagar N, Li X, Padi SK, Zhang Q, Tang MS, Guo B. Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death Dis. 2010;1(12): e105.","journal-title":"Cell Death Dis"},{"issue":"10","key":"3006_CR248","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.454","volume":"5","author":"Q Zhang","year":"2014","unstructured":"Zhang Q, Padi SK, Tindall DJ, Guo B. Polycomb protein EZH2 suppresses apoptosis by silencing the proapoptotic miR-31. Cell Death Dis. 2014;5(10): e1486.","journal-title":"Cell Death Dis"},{"issue":"6907","key":"3006_CR249","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/nature01075","volume":"419","author":"S Varambally","year":"2002","unstructured":"Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002;419(6907):624\u20139.","journal-title":"Nature"},{"issue":"10","key":"3006_CR250","doi-asserted-by":"publisher","first-page":"929","DOI":"10.2174\/1568009618666180315160125","volume":"18","author":"A Razdan","year":"2018","unstructured":"Razdan A, de Souza P, Roberts TL. Role of MicroRNAs in treatment response in prostate cancer. Curr Cancer Drug Targets. 2018;18(10):929\u201344.","journal-title":"Curr Cancer Drug Targets"},{"issue":"6","key":"3006_CR251","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41419-021-03854-x","volume":"12","author":"L Ding","year":"2021","unstructured":"Ding L, Wang R, Shen D, Cheng S, Wang H, Lu Z, et al. Role of noncoding RNA in drug resistance of prostate cancer. Cell Death Dis. 2021;12(6):590.","journal-title":"Cell Death Dis"},{"issue":"6","key":"3006_CR252","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s00345-018-2501-6","volume":"37","author":"H Samli","year":"2019","unstructured":"Samli H, Samli M, Vatansever B, Ardicli S, Aztopal N, Dincel D, et al. Paclitaxel resistance and the role of miRNAs in prostate cancer cell lines. World J Urol. 2019;37(6):1117\u201326.","journal-title":"World J Urol"},{"issue":"25","key":"3006_CR253","doi-asserted-by":"publisher","first-page":"19076","DOI":"10.1074\/jbc.M109.079525","volume":"285","author":"Y Fujita","year":"2010","unstructured":"Fujita Y, Kojima K, Ohhashi R, Hamada N, Nozawa Y, Kitamoto A, et al. MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression. J Biol Chem. 2010;285(25):19076\u201384.","journal-title":"J Biol Chem"},{"issue":"5","key":"3006_CR254","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/pros.21270","volume":"71","author":"XB Shi","year":"2011","unstructured":"Shi XB, Xue L, Ma AH, Tepper CG, Kung HJ, White RW. miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes. Prostate. 2011;71(5):538\u201349.","journal-title":"Prostate"},{"issue":"10","key":"3006_CR255","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.3390\/jcm4101853","volume":"4","author":"T Miyazaki","year":"2015","unstructured":"Miyazaki T, Ikeda K, Sato W, Horie-Inoue K, Okamoto K, Inoue S. MicroRNA library-based functional screening identified androgen-sensitive miR-216a as a player in bicalutamide resistance in prostate cancer. J Clin Med. 2015;4(10):1853\u201365.","journal-title":"J Clin Med"},{"issue":"2","key":"3006_CR256","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/bph.15300","volume":"178","author":"Y Wang","year":"2021","unstructured":"Wang Y, Chen J, Wu Z, Ding W, Gao S, Gao Y, et al. Mechanisms of enzalutamide resistance in castration-resistant prostate cancer and therapeutic strategies to overcome it. Br J Pharmacol. 2021;178(2):239\u201361.","journal-title":"Br J Pharmacol"},{"key":"3006_CR257","doi-asserted-by":"publisher","first-page":"11418","DOI":"10.1038\/ncomms11418","volume":"7","author":"SC Lin","year":"2016","unstructured":"Lin SC, Kao CY, Lee HJ, Creighton CJ, Ittmann MM, Tsai SJ, et al. Dysregulation of miRNAs-COUP-TFII-FOXM1-CENPF axis contributes to the metastasis of prostate cancer. Nat Commun. 2016;7:11418.","journal-title":"Nat Commun"},{"issue":"8","key":"3006_CR258","doi-asserted-by":"publisher","first-page":"14055","DOI":"10.1002\/jcb.28680","volume":"120","author":"W Chen","year":"2019","unstructured":"Chen W, Yao G, Zhou K. miR-103a-2-5p\/miR-30c-1-3p inhibits the progression of prostate cancer resistance to androgen ablation therapy via targeting androgen receptor variant 7. J Cell Biochem. 2019;120(8):14055\u201364.","journal-title":"J Cell Biochem"},{"issue":"2","key":"3006_CR259","first-page":"403","volume":"31","author":"A Gordanpour","year":"2011","unstructured":"Gordanpour A, Stanimirovic A, Nam RK, Moreno CS, Sherman C, Sugar L, et al. miR-221 Is down-regulated in TMPRSS2:ERG fusion-positive prostate cancer. Anticancer Res. 2011;31(2):403\u201310.","journal-title":"Anticancer Res"},{"issue":"19","key":"3006_CR260","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1038\/onc.2013.200","volume":"33","author":"CJ Kao","year":"2014","unstructured":"Kao CJ, Martiniez A, Shi XB, Yang J, Evans CP, Dobi A, et al. miR-30 as a tumor suppressor connects EGF\/Src signal to ERG and EMT. Oncogene. 2014;33(19):2495\u2013503.","journal-title":"Oncogene"},{"issue":"9","key":"3006_CR261","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1111\/febs.12236","volume":"280","author":"M Hart","year":"2013","unstructured":"Hart M, Wach S, Nolte E, Szczyrba J, Menon R, Taubert H, et al. The proto-oncogene ERG is a target of microRNA miR-145 in prostate cancer. Febs j. 2013;280(9):2105\u201316.","journal-title":"Febs j"},{"issue":"1","key":"3006_CR262","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.juro.2014.01.107","volume":"192","author":"I Casanova-Salas","year":"2014","unstructured":"Casanova-Salas I, Rubio-Briones J, Calatrava A, Mancarella C, Masi\u00e1 E, Casanova J, et al. Identification of miR-187 and miR-182 as biomarkers of early diagnosis and prognosis in patients with prostate cancer treated with radical prostatectomy. J Urol. 2014;192(1):252\u20139.","journal-title":"J Urol"},{"issue":"13","key":"3006_CR263","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1038\/sj.onc.1208371","volume":"24","author":"AB McKie","year":"2005","unstructured":"McKie AB, Douglas DA, Olijslagers S, Graham J, Omar MM, Heer R, et al. Epigenetic inactivation of the human sprouty2 (hSPRY2) homologue in prostate cancer. Oncogene. 2005;24(13):2166\u201374.","journal-title":"Oncogene"},{"issue":"8","key":"3006_CR264","first-page":"3714","volume":"9","author":"W Zhou","year":"2017","unstructured":"Zhou W, Huang S, Jiang Q, Yuan T. Suppression of miR-4735-3p in androgen receptor-expressing prostate cancer cells increases cell death during chemotherapy. Am J Transl Res. 2017;9(8):3714\u201322.","journal-title":"Am J Transl Res"},{"issue":"7","key":"3006_CR265","first-page":"8394","volume":"8","author":"X Sun","year":"2015","unstructured":"Sun X, Yang Z, Zhang Y, He J, Wang F, Su P, et al. Prognostic implications of tissue and serum levels of microRNA-128 in human prostate cancer. Int J Clin Exp Pathol. 2015;8(7):8394\u2013401.","journal-title":"Int J Clin Exp Pathol"},{"issue":"15","key":"3006_CR266","doi-asserted-by":"publisher","first-page":"4183","DOI":"10.1158\/0008-5472.CAN-14-0404","volume":"74","author":"M Jin","year":"2014","unstructured":"Jin M, Zhang T, Liu C, Badeaux MA, Liu B, Liu R, et al. miRNA-128 suppresses prostate cancer by inhibiting BMI-1 to inhibit tumor-initiating cells. Cancer Res. 2014;74(15):4183\u201395.","journal-title":"Cancer Res"},{"issue":"6","key":"3006_CR267","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41419-021-03854-x","volume":"12","author":"L Ding","year":"2021","unstructured":"Ding L, Wang R, Shen D, Cheng S, Wang H, Lu Z, et al. Role of noncoding RNA in drug resistance of prostate cancer. Cell Death Dis. 2021;12(6):590.","journal-title":"Cell Death Dis"},{"issue":"3","key":"3006_CR268","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2017.288","volume":"50","author":"D Poel","year":"2018","unstructured":"Poel D, Buffart TE, Oosterling-Jansen J, Verheul HM, Voortman J. Evaluation of several methodological challenges in circulating miRNA qPCR studies in patients with head and neck cancer. Exp Mol Med. 2018;50(3): e454.","journal-title":"Exp Mol Med"},{"issue":"8","key":"3006_CR269","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0268958","volume":"17","author":"T Kupec","year":"2022","unstructured":"Kupec T, Bleilevens A, Iborra S, Najjari L, Wittenborn J, Maurer J, et al. Stability of circulating microRNAs in serum. PLoS ONE. 2022;17(8): e0268958.","journal-title":"PLoS ONE"},{"issue":"1","key":"3006_CR270","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1038\/s41598-024-52681-5","volume":"14","author":"US Sandau","year":"2024","unstructured":"Sandau US, Wiedrick JT, McFarland TJ, Galasko DR, Fanning Z, Quinn JF, et al. Analysis of the longitudinal stability of human plasma miRNAs and implications for disease biomarkers. Sci Rep. 2024;14(1):2148.","journal-title":"Sci Rep"},{"issue":"1","key":"3006_CR271","doi-asserted-by":"publisher","first-page":"10306","DOI":"10.1038\/s41598-018-28748-5","volume":"8","author":"D Sanz-Rubio","year":"2018","unstructured":"Sanz-Rubio D, Martin-Burriel I, Gil A, Cubero P, Forner M, Khalyfa A, et al. Stability of circulating exosomal miRNAs in healthy subjects. Sci Rep. 2018;8(1):10306.","journal-title":"Sci Rep"},{"issue":"1","key":"3006_CR272","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12967-018-1592-6","volume":"16","author":"B Malla","year":"2018","unstructured":"Malla B, Aebersold DM, Dal Pra A. Protocol for serum exosomal miRNAs analysis in prostate cancer patients treated with radiotherapy. J Transl Med. 2018;16(1):223.","journal-title":"J Transl Med"}],"updated-by":[{"DOI":"10.1007\/s12032-026-03486-1","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000}}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03006-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-03006-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03006-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:02:15Z","timestamp":1792735335000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-03006-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":272,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["3006"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-03006-7","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"assertion":[{"value":"15 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been retracted. Please see the Retraction Notice for more detail:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12032-026-03486-1","URL":"https:\/\/doi.org\/10.1007\/s12032-026-03486-1","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not required for this study.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"454"}}